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Abstract
DAX-1, an orphan nuclear hormone receptor, acts mainly as a repressor
through transcriptional protein complexes. Its unique structure and specific
expression raises questions as to what its precise interactions are and how it
mediates its repressive function. While it is known to play a role in sexual
development and adrenal insufficiency, expression in certain types of cancer
suggests additional functions and interactions. Knock in of DAX-1 into a low-DAX-1
expressing cancer cell line has been previously observed to increase apoptosis,
while, inversely, down in a high-DAX-1 expressing cancer cell line shows a decrease
in apoptosis. Target genes that belong to the TNFα and BCL-2 families have shown
changes in expression correlating to the modified levels of DAX-1 in knock-down
experiments. Direct regulation of BCL-2, one of the target genes of interest, was
investigated further based on mirrored expression changes of DAX-1 in knock-down
and knock in experiments through ChIP experiments. These findings emphasize a
significant role of DAX-1 in moderating apoptosis in a breast cancer cell line.
In the context of undifferentiated mouse embryonic stem cells, Dax-1 is
highly expressed and has been shown to be an important contributor to the
pluripotent state. Potential downstream targets of Dax-1 were previously identified
based on significant changes in expression when Dax-1 expression was down
regulated. Two methods, siRNA and CRISPR-Cas9, were used to decrease Dax-1
expression in the E14 mouse embryonic stem cell line. Direct interactions and other
novel stem cell factors were confirmed using analysis of publically available ChiP1

seq data. Ultimately, while Dax-1 is not a master regulator, its transcriptional
control of specific genes that are key in the maintenance of pluripotency is an
important component of stem cell growth and differentiation. Bioinformatic analysis
of ChIP-seq experiments brought to light general patterns as to how Dax-1
contributes to pluripotency, and additional ontologies of Dax-1 target genes for
future studies.

2

Table of Contents
Page Number
Abstract ....................................................................................................................................................... 1
Table of Contents ..................................................................................................................................... 3
Acknowledgements ................................................................................................................................ 4
List of Figures............................................................................................................................................ 5
List of Tables ............................................................................................................................................. 8
List of Abbreviations ........................................................................................................................... 10
Chapter 1
Nuclear Hormone Receptors and DAX-1
Introduction........................................................................................................................................................ 13
Chapter 2
Manipulation of DAX-1 Expression in a Range of Model Systems
Introduction........................................................................................................................................................ 19
Methods ................................................................................................................................................................ 29
Results................................................................................................................................................................... 38
Discussion............................................................................................................................................................ 46
Chapter 3
DAX-1 Mediates Expression of Apoptosis-Inducing Genes in Human Breast Cancer
Introduction........................................................................................................................................................ 47
Materials and Methods................................................................................................................................... 61
Results................................................................................................................................................................... 70
Discussion............................................................................................................................................................ 87
Chapter 4
Dax-1 Knock-down Effects on Pluripotent Gene Network in Mouse Embryonic Stem
Cells
Introduction........................................................................................................................................................ 89
Materials and Methods................................................................................................................................... 94
Results................................................................................................................................................................... 97
Discussion......................................................................................................................................................... 106
Chapter 5
Functional enrichment analysis of Dax-1 ChIP-seq high-throughput data
Introduction..................................................................................................................................................... 108
Materials and Methods................................................................................................................................ 113
Results................................................................................................................................................................ 116
Discussion......................................................................................................................................................... 123
End Summary ....................................................................................................................................... 125
References............................................................................................................................................. 127

3

Acknowledgements
Principal Investigator
Dr. Christina Tzagarakis-Foster
Thesis Committee Members
Dr. James Sikes
Dr. Cary Lai
Tzagarakis-Foster Laboratory
Hai Nguyen
Amy Scandurra
Michael Heskett
Victor Gavallos
University of San Francisco Biology Graduate Students
Carolyn Tu
Cendy Valleoseguera
Vivian Young
University of San Francisco Biology Department Faculty and Staff

Words cannot fully express how grateful I am for the support of my PI Dr.
Tzagarakis-Foster and labmates. This is sepecially dedicated to my late father, who
couldn’t see this to completion but continues to be a source of strength and
inspiration.

4

List of Figures
Figure 1-1. Functional domain structures of a general nuclear hormone receptor and
DAX-1............................................................................................................................................................17
Figure 1-2. X-Ray Crystallography Illustration of Mouse Dax-1 Ligand Binding
Domain.........................................................................................................................................................18
Figure 2-1. pcDNA3.1 vector (Life Technologies)......................................................................21
Figure 2-2. RNA interference mechanism.....................................................................................24
Figure 2-3. CRISPR-Cas9 knock-down mechanism...................................................................28
Figure 2-4. Structure summary of the CRISPR-Cas9 optimized plasmid pX459..........34
Figure 2-5. CRISPR targets within the Dax-1 gene (first exon)............................................36
Figure 2-6. CRISPR targets within the Dax-1 gene (second exon).....................................37
Figure 2-7. Introduction of DAX-1 expression in MCF7 cells by transient transfection
with pCDNA DAX-1..................................................................................................................................40
Figure 2-8. siRNA DAX-1 knock-down in MCF10A....................................................................41
Figure 2-9. siRNA Dax-1 knock-down in mESC...........................................................................42
Figure 2-10. Dax-1 specific CRISPR-Cas9 plasmid development........................................43
Figure 2-11. CRISPR Dax-1 knock-down in mESC.....................................................................45
Figure 3-1. Estimated Cancer Deaths in the US..........................................................................49
Figure 3-2. Workflow of PCR Array.................................................................................................50
Figure 3-3. TNFα pathway, with the major interactions leading to either cell
proliferation or apoptosis through the triggering of the caspase cascade.....................53
Figure 3-4. BCL-2 family apoptosis pathway...............................................................................55
Figure 3-5. Annexin V and PI staining of apoptotic cells........................................................59

5

Figure 3-6. Workflow of X-ChIP Assay (AbCam)........................................................................60
Figure 3-7. Targeted regions of the BCL-2 and BAX promoter...........................................68
Figure 3-8. Cell flow cytometry of Annevin V and propidium iodide stained MCF7
cells untreated and treated with pcDNA-DAX1..........................................................................71
Figure 3-9. qPCR results of the anti-apoptotic genes tested in the MCF10A knockdown total mRNA samples...................................................................................................................74
Figure 3-10. qPCR results of the pro-apoptotic genes tested in the MCF10A knockdown total mRNA samples...................................................................................................................76
Figure 3-11. qPCR results of the anti-apoptotic genes tested in the MCF7 knockdown total mRNA samples...................................................................................................................79
Figure 3-12. qPCR results of the pro-apoptotic genes tested in the MCF7 knockdown total mRNA samples...................................................................................................................80
Figure 3-13. Western blot of candidate DAX-1 targets BCL-XL and BAX........................84
Figure 3-14. Chromatin immunoprecipitation (ChIP) experiments targeting DAX-1
binding to the BCL-2 promoter..........................................................................................................86
Figure 4-1. Stem cell origins in the mammalian embryo........................................................91
Figure 4-2. qPCR results of siRNA Dax-1 knock-down mESC...............................................98
Figure 4-3. qPCR results of CRISPR Dax-1 knock-down mESC.........................................102
Figure 5-1. Statistical analysis of ChIP-seq data using the GREAT online annotation
software.....................................................................................................................................................112
Figure 5-2. Selected Ontology results from processing DAX1_BED1 file through the
online GREAT program.......................................................................................................................115

6

Figure 5-3. Top five interactions in Dac-1 ChIP-seq interactions obtained through
analysis of ontology data from GREAT by PCR, Clustal, and GGplot packages in R
language....................................................................................................................................................117

7

List of Tables
Table 2-1. siRNA sequences for MCF10A treatment................................................................32
Table 2-2. siRNA sequences for mESC treatment......................................................................32
Table 2-3. Sense and anti-sense sequences for oligonucleotides constructed using
the online CRISPR Design web program to target the Dax-1 gene.....................................35
Table 3-1. Anti-apoptotic candidate target genes......................................................................56
Table 3-2. Pro-apoptotic candidate target genes.......................................................................57
Table 3-3. Thermocycler conditions and steps for standard PCR......................................62
Table 3-4. Thermocycler conditions and steps in the two-step amplification program
for qPCR.......................................................................................................................................................63
Table 3-5. Primers for apoptosis qPCR analysis.........................................................................65
Table 3-6. Monoclonal Antibodies used for Western Blotting.............................................66
Table 3-7. Antibodies used for ChIP assay....................................................................................69
Table 3-8. Primer sets corresponding to promoter regions of BCL-2 and BAX............69
Table 3-9. Comparison of candidate genes in MCF10A and MCF7 cells...........................83
Table 4-1. Dax-1 candidate target genes in mESC and their roles in mediating
pluripotency and differentiation.......................................................................................................93
Table 4-2. Pluripotency Candidate gene primers......................................................................95
Table 4-3. Comparison of siRNA and CRISPR Dax-1 candidate gene results..............105
Table 5-1. Parameters for GREAT Version 3.0.0 online analysis......................................114
Table 5-2. Top Five Interactions in Dax-1 ChIP-seq interactions....................................118
Table 5-3. Selected genes from the top five ontologies........................................................119

8

Table 5-4. Genes from the top five ontologies that overlap with mESC pluripotency
project........................................................................................................................................................122

9

List of Abbreviations
AHC:

Adrenal Hypoplasia Congenita

Ago2:

Argonaute-2

AR:

Androgen Receptor

BADGE:

Bisphenol A diglycidyl ether; 2,2'-[(1-Methylethylidene)bis(4,1phenyleneoxymethylene)]bis-oxirane

BAX:

Bcl-2-associated X Protein

BAK:

Bcl-2 Homologous Antagonist Killer

BCL-2:

B-cell lymphoma 2

BCL-XL:

B-cell lymphoma extra large

BCL-XS:

B-cell lymphoma extra small

BH1-4:

Bcl-2 homology domain 1 through 4

Cas:

CRISPR Associated Proteins

Caspases: Cysteine-aspartic Proteases; Cysteine-dependent aspartate-directed
proteases
cDNA:

Complimentary DNA

ChIP:

Chromatin Immunoprecipitation

ChIP-seq: Direct High-throughput Chromatin Immunopreciptation Sequencing
CRISPR:

Clustered Regularly Interspaced Short Palindromic Repeats

crRNA:

CRISPR repeat-spacer RNA

DAX-1:

Dosage Sensitive Sex Reversal Adrenal Hypoplasia Congenita, critical
region on the X Chromosome, Gene 1

DBD:

DNA Binding Doman

10

DMEM:

Dulbecco’s Modified Eagle Medium

DNA:

Deoxyribonucleic Acid

DSS:

Dosage Sensitive Sex Reversal

ER:

Estrogen Receptor

ERα:

Estrogen Receptor alpha

FBS:

Fetal Bovine Serum

FITC:

Fluorescein Isothiocyanate

GAPDH:

Glyceraldehyde 3-Phosphate Dehydrogenase

GRTH:

Gonadotropin-regulated Testicular Helicase

H:

The amino acid histidine

HDR:

Homology Directed Repair

I:

The amino acid isoleucine

IgG:

Immunoglobulin G

Indel:

Insertion/deletion mutation

LBD:

Ligand Binding Doman

L:

The amino acid leucine

mESC:

Mouse Embryonic Stem Cell

MOMP:

Mitochondrial Outer Membrane Permeabilization

mRNA:

Messenger RNA

NC:

Negative Control

NEAA:

Non-essential Amino Acids

NHEJ:

Nonhomologous End Joining

NHR:

Nuclear Hormone Receptor

11

NR:

Nuclear Receptor

RBS:

Phosphate Buffered Saline

PCR:

Polymerase Chain Reaction

PI:

Propidium Iodide

PS:

Phosphatidylserine

PVDF:

Polyvinylidene Fluoride

qPCR:

Quantitative Polymerase Chain Reaction

RNA:

Ribonucleic Acid

RNAi:

RNA Interference

RISC:

RNA Interference Silencing Complex

RT-PCR: Real Time Polymerase Chain Reaction
SF-1:

Steroidogenic Factor-1

siRNA:

Short Interfering RNA

shRNA:

Short-hairpin RNA

TBS:

Tris Buffered Saline

TNFα:

Tumor Necrosis Factor alpha

TRADD:

TNFRSF1A-associated via death domain

TSS:

Transcription Start Site

UT:

Untreated

WT:

Wild-type

x:

represents any amino acid in the protein sequence

X-ChiP:

Cross-linked ChiP

12

Chapter 1
Nuclear Hormone Receptors and DAX-1
Introduction
Nuclear hormone receptors (NHRs) are a superfamily of eukaryotic
transcription factors that are involved in the regulation of specific target genes for
various biological processes through the response to hormones and other metabolic
ligands [1]. These various proteins share a conserved general domain structure, as
illustrated in Figure 1-1A: an N-terminal domain (A/B), a DNA binding domain, or
DBD (C), a flexible hinge region (D), a ligand binding domain, or LBD (E), and a Cterminal domain (F). There are seven subfamilies, identified as NR0 through NR6,
based on sequence similarity in the conserved DBD and LBD regions of the genes
[2]. This sub-categorization helps dictate the gene nomenclature rules.
These proteins generally have an effect on gene transcription upon binding
of a ligand [3]. In general, once these transcription factors bind ligand and are
activated, they can bind to specific sequences, also known as hormone response
elements (HREs), present within the regulator regions of target genes. Typically,
NHRs carry out their activity by forming dimers on these response element
sequences. The combination of NHRs may either be as homodimers, composed of
two identical receptors, or as heterodimers, composed of different receptors [4].
NHRs that act as activators or coactivators contain LxxLL (Leu-x-x-Leu-Leu)
motifs in their primary amino acid sequence, which manifest as alpha helices in the
protein structure. Also known as NR boxes, the sequence allows for protein-protein
interactions, and therefore the formation of transcriptional factor complexes [5, 6].
13

In contrast, NHRs that generally act as repressors or corepressors have a consensus
motif known as a CoRNR box, consisting of an Lxx H/I xxx I/L motif that is
manifested as an extended helix, and interacts with similar residues such as the
LxxLL motif. The variance in the length of the helical interface allows for a difference
in the transcription factor complexes [7].
In humans, there have been 48 different NHRs identified to date. Mice, with
47 known NHRs, share a similar number of this group of proteins encoded in their
genome. This conservation of nuclear receptors is reflected in only members of the
animal kingdom [8], and is not observed in any other relatives of metazoans [9].
NHRs have been studied in great detail in numerous model systems because of their
involvement with key signaling pathways and the potential for targeting in diseases.
Proteins within the NHR family can be further categorized into three groups:
steroid hormone receptors, non-steroid hormone receptors, and orphan receptors.
Steroid hormone receptors respond to steroids, while non-steroid hormone
receptors interact with other ligands such as thyroid hormone, retinoic acid, and
vitamin D2. Lastly, the remaining NHRs that have no known ligand interaction are
classified as orphan nuclear hormone receptors. [10]
DAX-1 is a unique orphan nuclear hormone receptor that is encoded by the
NR0B1 gene. The protein name stands for dosage sensitive sex reversal, adrenal
hypoplasia congenital on the X chromosome, gene 1; for humans, it is written out as
DAX-1, while for mice it is noted as Dax-1 [11]. The protein product of the human
NR0B1 gene is 470 amino acids, pieced together from two exons. In contrast to the
typical NHR structure, the DAX-1 protein has a repetitive domain consisting of 3.5
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alanine/glycine rich repeats that each are about 65 to 70 amino acids long in place
of the DNA binding domain, as shown in Figure 1-1B. It shares this unusual domain
with a close cousin within the NHR family called SHP (small heterodimer partner),
encoded by the NR0B2 gene [12] [13].
While the ligand-binding domain is conserved, DAX-1 is identified as an
orphan due to no known ligand interaction. The lack of the DNA binding domain, no
known ligand interaction, and LxxLL sites strongly implies that DAX-1 primarily
functions within the cell through interactions with other proteins, such as Wilm’s
tumor 1 (WT1) and steroidogenic factor 1 (SF-1) [14] rather than direct binding to
DNA as a transcriptional factor. And despite having LxxLL sites, which is typical of
coactivators, DAX-1 has been shown to act as a corepressor [15]. X-ray
crystallographic data has provided some insight as to how DAX-1 mediates its
repressive function through binding directly to other NHR proteins. The entire
protein has yet to be isolated and crystallized, but the LBD region of DAX-1 has been
successfully crystallized in complex with the protein LRH-1, as illustrated in Figure
1-2. The site of interaction with LRH-1 is at an extended surface, therefore occluding
binding of other co-activators to LRH-1 [16]. This type of protein-protein interaction
is a likely explanation of why DAX-1 is a strong transcriptional repressor.
The original discovery of DAX-1 was through duplications in the gene that
caused males to phenotypically appear female, corresponding to the “dosagesensitive sex reversal” portion of the name [17]. Additional research found that
mutations within the same gene led to X-linked adrenal hypoplasia congenital
(AHC), an uncommon disorder of adrenal gland development [18]. Outside of these
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diseases, DAX-1 has a restricted expression pattern. It is highly expressed in stem
cells before differentiation, and is noted to contribute to early embryogenesis [11].
In an adult organism, expression is limited to select steroidogenic organs, especially
within the hypothalamus-pituitary-adrenalgonadal axis [19].
More recently, there has been a proposed role of DAX-1 in various cancers, in
addition to its role in normal cells. Numerous NHRs have been linked to the
pathogenesis and treatment of various cancers [20], and DAX-1 is no exception. Its
strong influence on pluripotency, a characteristic seen also in a subset of cancer
cells, and unusual structure brought DAX-1 into the spotlight as a candidate for
cancer therapy [21]. In this thesis, we study the specific molecular mechanisms and
interactions by which Dax-1 functions within mouse ES cells and human DAX-1’s
influence on processes within normal and breast cancer cells.

16

A.

B.

Figure 1-1. Functional domain structures of a general nuclear hormone
receptor and DAX-1. A. The general nuclear hormone receptor gene regions with
the following labeled structures: an N-terminal domain (A/B), a DNA binding
domain, or DBD (C), a hinge region (D), a ligand binding domain (E), and a Cterminal domain (F), and B. the DAX-1 protein structure, with the 3.5
alanine/glycine rich repeats on the N-terminal end (R) and a conserved LBD-like
domain (E).
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Figure 1-2. X-Ray crystallography illustration of mouse Dax-1 ligand binding
domain. Structure is based on the available image of Dax-1 in complex with LRH-1
(Fletterick Group, pdb file 3F5C). The chains are colored from blue to red, in the
direction of the N-terminus to C-terminus. Figure generated by P. Foster.
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Chapter 2
Manipulation of DAX-1 Expression in a Range of Model Systems
Introduction
As previously mentioned, DAX-1 expression is restricted to stem cells and a
number of organs within a mature organism. The research detailed in this thesis
examines the role of DAX-1 in human breast cancer cells as well as mouse
embryonic stem cells. Both these research projects required a means to study and
manipulate DAX-1 expression in order to explore the outcome of this change. For
these experiments, the human cell lines MCF7 (epithelial breast cancer cells) and
MCF10A (mammary epithelial cells) and the mouse embryonic stem cell line E14
were used. MCF7 cells are typically used as a triple positive cell culture model,
because these cells express estrogen receptor, progesterone receptor, and HER2
[22]. Transient transfection assays were used to exogenously express DAX-1 in the
cell types with little to no DAX-1 expression, while RNAi and CRISPR methods were
utilized to reduce or eliminate DAX-1 expression in cell lines with endogenous
expression of DAX-1. Once these models had been established, we could explore the
outcome of changes in DAX-1 expression in both human cancer cells (Chapter 3) and
mouse embryonic stem cells (Chapter 4).

pcDNA expression vector
In order to introduce DAX-1 into the MCF7 cells, an expression plasmid
containing the entire human DAX-1 coding sequence was utilized. The expression
vector used for these experiments was pcDNA3.1, which contains unique restriction
19

enzyme target sites in both directions for sequence insertion (Figure 2-1). Other key
features of the plasmid include the genes for ampicillin and neomycin resistance,
which aid in the selection process after transformation into competent E. coli. The
entire human DAX-1 coding sequence was amplified by PCR and cloned into the
plasmid using the BamHI and XhoI restriction enzyme sites. Confirmation of correct
insertion of DAX-1 into pcDNA3.1 was confirmed by DNA sequencing. This
expression plasmid was previously generated by C. Tzagarakis-Foster.

20

Figure 2-1. pcDNA3.1 vector (Life Technologies) utilized in transient
transfection assays.

21

RNA interference
RNA interference is a gene silencing technique that utilizes non-coding RNAs
to target messenger RNA present in an organism and affect gene expression before
translation into protein [23]. Numerous forms of RNA can be utilized, ranging from
double stranded RNA to short hairpin RNA, with different structures and stability.
While this phenomenon is conserved across most complex organisms, it was not
exploited until the discovery of sequence-specific short interfering RNAs (siRNAs).
These are 21 nucleotide long sequences, with 19 of those nucleotides specific to the
target sequence to form a duplex, and the remaining 2 unpaired at the 3’ ends [24].
The pathway of RNA interference, illustrated in Figure 2-2, starts in the
cytoplasm when Dicer, an RNAse III endonuclease, processes siRNA precursors such
as dsRNA or shRNAs. Certain kinds of optimized techniques in research skip this
processing step and may allow for the transfection of the shortened siRNA from the
start. A “mature” siRNA molecule then enters into a multi-protein RNA-induced
silencing complex, or RISC. The completed complex pairs the siRNA with the target
mRNA at the complementary region, and the protein Argonaut-2 (Ago2) mediates
the cleavage of the siRNA-mRNA pair within the complex. Other notable proteins
involved in RISC include a transactivating response RNA-binding protein, or TRBP,
that helps facilitate the transfer of Dicer-generated fragments to Ago2 for RNA
degradation. While there are cleavage independent mechanisms to block translation
of the targeted mRNA, the formation of the complex allows for the target to be
broken up several times. The resulting smaller RNA fragments are ultimately
degraded by exoribonucleases, and the loss of the targeted mRNA in the cell reduces
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the amount of protein produced from translation [25]. This technique is widely used
in research for many model organisms, and was applied to both the MCF7 human
breast cancer cells and the E14 mouse embryonic stem cells in experiments to
knock-down endogenous DAX-1 expression.
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Figure 2-2. RNA interference mechanism. Starting materials range from shorthairpin RNA (shRNA) or double stranded RNA (dsRNA) that is then matured into a
simplified form of single stranded RNA, or initially short interfering RNA (siRNA)
that is already shortened to a length of twenty to thirty base pairs long. Once a
target messenger RNA is found through a section complementary to the siRNA, RISC
is formed to capture and degrade the mRNA, resulting in a loss of gene expression at
the RNA level.
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CRISPR-Cas
A recent technique utilizing an endogenous mechanism called CRISPR-Cas
has been propelled as a more permanent modification to protein expression. The
name is short for “clustered regularly interspaced short palindromic repeats –
CRISPR associated proteins.” In contrast to commonly used techniques, such as
RNAi that targets a gene at the RNA level in order to reduce its expression, CRISPR
affects cell functions through genomic editing [26].
The technique was developed based on microbial immune systems, where
RNA-guided endonucleases can interact with specific targets, typically exogenous
DNA from viruses or other bacteria, and allows the organism to both eliminate the
invading genomic information as well as acquire immunity against similar viruses
and plasmids [27]. Optimized plasmids have been developed to contain core
elements of the CRISPR-Cas system, selection genes for transformation and cloning,
and specific restriction enzymes sites for the insertion of a target guide sequence.
One of the main elements of the most commonly used optimized system is
Cas9, part of the Cas protein family. This family, whose name is short for “CRISPRassociated genes,” consists of microbial endonucleases than can utilize short RNA
sequences as guides to cause damage to genomic DNA [28]. Cas9 is specifically used
for research applications because while other systems may require a complex of
multiple Cas proteins, Cas9 is large protein that alone is sufficient for generating a
mature guide RNA and cleaving the target DNA [29].
The endonuclease can only act on a target DNA by using a guide sequence,
often referred to as CRISPR repeat-spacer RNA, or crRNA. This fragment contains
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conserved repeat fragments and a variable spacer sequence that is complementary
to a target region [30]. While the length of this sequence varies in size depending on
the type of Cas protein used, the Cas9 protein is able to create and use a guide with a
target sequence as short as 21 nucleotides long. Together with a trans-activating
crRNA (tracrRNA), an RNA duplex is formed and matured to form a hybrid, acting as
a complete guide for Cas9 [31]. This allows for Cas9 to situate itself at the target
location with base-pair matching of the guide RNA and cause DNA damage (Figure
2-3).
The damage caused by the Cas9 endonuclease is a double-stranded break
that can be repaired in two ways. Nonhomologous end joining, or NHEJ, is an
imprecise type of repair that through immediate ligation to close the break
introduces insertion and deletion (or indel) mutations that vary in length [32].
When applied to damage within a gene, this disrupts the translational reading
frame; if applied in a noncoding region, this can potentially disrupt a binding site of
transcriptional factors. Another type of DNA repair is homology-directed repair, or
HDR, which utilizes a template to repair the site of damage. Through the use of the
of a donor template, more precise point mutations or insertions can occur at the site
of damage [33].
Additional genomic engineering applications of the Cas9-based technique can
result in sequence specific insertions, large deletions, genomic rearrangements
through inversions or translocations, gene activations, epigenetic modification, or
tagging of genomic loci [34]. Applications of this technique include early treatment
in haploid cells to increase the frequency of successful gene modification without
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selection [35], in human pluripotent stem cells [36], and even in entire living
organisms [37]. CRISPR-Cas9 is also applicable to affect multiple gene targets with
the inclusion of several guide sequences within the optimized plasmid [38], further
expanding the applications while maintaining the simplicity of the system. In the
context of this thesis, CRISPR-Cas9 was applied to target the coding sequence of
mouse Dax-1 at multiple locations through the design of several guide sequences.
The sequences were used individually in CRISPR-Cas9 transfection and cells were
selected for proper Dax-1 deletion before further analysis in Chapter 4.
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A.

B.

Figure 2-3. CRISPR-Cas9 knock-down mechanism. A. A complete CRISPR-Cas9
plasmid includes a sequence for the Cas9 endonuclease, an inserted guide sequence,
and selection genes. The plasmid is transfected into cells or an organism and allows
for internal production of the key CRISPR system elements. The ribonucleic-protein
complex of Cas9 with a mature guide allows for DNA damage at a target site. This
damage can be repaired by either NHEJ or HDR DNA repair mechanisms. B. Based
on the type of repair and Cas9 used, there are a number of different outcomes to
CRISPR modifications. Without a provided template, the site of damage can be
repaired through non-homology end joining and result in random insertions and
deletions at the target site. With a template, homology directed repair allows for
either the insertion of a provided sequence or an inversion of the targeted section.
Deactivation of Cas9 can eliminate the endonuclease aspect and allow for guide
direct tagging or modification without damage to the genome.
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Methods
Cell Culture
MCF7 epithelial breast cancer cells were obtained from American Type
Culture Collection. The cells were cultured and passaged in a 5% carbon
dioxide tissue culture incubator at 37°C. Cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) with L-glutamine and without phenol red,
supplemented with 10% charcoal-stripped fetal bovine serum (American
Type Culture Collection, treated with dextran coated charcoal from SigmaAldrich) and 1% penicillin/streptomycin (Gibco).
MCF10A human mammary epithelial cells were obtained from American
Type Culture Collection. The cells were cultured in the same incubator
conditions as MCF7 cells. Complete MCF10A media used Dulbecco’s Modified
Eagle Medium (DMEM) with phenol red and additional supplements of 10%
fetal bovine serum (American Type Culture Collection), 1%
penicillin/streptomycin (Gibco), 100 ng/mL of cholera toxin (Sigma-Aldrich),
and mammary epithelial growth medium (MEGM) SingleQuot additives
[hydrocortisone (05 μg/mL, human EGF (10ng/mL), insulin (10 μg/mL)]
(Lonza Corporation).
The E14 mouse embryonic stem cell line was donated from the lab of Dr.
Mohammed El Majdoubi, from Dominican University of California in San
Rafael, CA. The feeder-free cells were cultured and passaged in a 5% carbon
dioxide tissue culture incubator at 37°C in 0.1% gelatin-coated flasks. The
media used for the cultured cells was Dulbecco’s Modified Eagle Medium
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(DMEM) with phenol red, GlutaMax, and 4.5 g/L D-glucose. For the complete
media, additional supplements of 15% fetal bovine serum (American Type
Culture Collection), 1% penicillin/streptomycin (Gibco), 1% non-essential
amino acids (Gibco), 1,000 U/mL Leukemia Inhibitory Factor (SigmaAldrich), and 0.1mM β-mercaptoethanol (Promega) were added through a
sterile filter. This combination is modified from those outlined by the Cho
Lab [39].
To passage cells, flasks were washed with phosphate buffered saline (PBS)
and treated with Trypsin-EDTA (0.05%) with phenol red (Gibco) at 37°C
until cells lifted from the flask. Cells were then re-suspended and passaged,
ranging from 1:5 to a 1:10 ratio.

DAX1 knock-in into MCF7 cells
A pcDNA3.1-DAX1 construct was provided by Dr. Christina TzagarakisFoster, and transfected into the MCF7 cells using Lafectine RU50 according to
protocol, using 50uL for every μg of plasmid. Treated cells were initially
seeded in “low” media, composed of DMEM without phenol red
supplemented with 1% fetal bovine serum, for up to 24 hours before
treatment in complete media. Cells were treated for 48 hours before
collection. Samples collected from treated cells are referred to herein as
“MCF7+DAX-1”.
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DAX1 knock-down in MCF10A and E14 cells with siRNA
A set of three synthetic double stranded stealth siRNA oligonucleotides
designed to target the human DAX-1 gene were obtained from Life
Technologies. The three siRNAs, which targeted human DAX-1 in different
regions of the gene, were used for transfection into MCF10A cells, as shown
in Table 2-1. Three synthetic Silencer pre-designed small interfering RNA
(siRNA) oligonucleotides targeting mouse Nr0b1 (Life Technologies) were
utilized for Dax-1 knock-down, with sequences and targeting sites listed in
Table 2-2. Ambion Silencer Negative Control #1 was used as the nontargeting siRNA sample. Six-well plates were seeded with 500,000 MCF10A
cells per well in complete media and reverse transfected using Lafectine
RU50 (MednaBio). The total concentration of the siRNA for MCF10A cells was
300pmol for each well, while two concentrations of 20pmol and 80pmol of
each individual siRNA was used for the mouse embryonic stem cells. Mouse
cells were treated a second time with a change of media after 24 hours.
Collections for mRNA and protein lysate analysis were carried out after 48
hours.

Statistical Anaylsis
Data from the qPCR analysis are presented with the mean + standard
deviation of triplicate experiments, normalized using GAPDH Cq values.
Statistical significance is calculated using the two-tailed t-test formula built
into Microsoft Excel. A single asterisk (*) represents samples that were
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p<0.05, a double asterisk (**) represents samples that were p<0.005, and a
triple asterisk (***) represents samples that were p<0.001.

Table 2-1. siRNA sequences for MCF10A treatment.
siRNA

Sequence

Target Region

hDAX-1 siRNA 1

CCCAUGACAGAUUCAUCGAACUUAA

Exon 2

UUAAGUUCGAUGAAUCUGUCAUGGG Position 1290
hDAX-1 siRNA 2

CCCAUGACAGAUUCAUCGAACUUAA

Exon 2

UUAAGUUCGAUGAAUCUGUCAUGGG Position 1383
hDAX-1 siRNA 3

CAGUGGCAGGGCAGCAUCCUCUACA

Exon 1

UGUAGAGGAUGCUGCCCUGCCACUG

Position 44

Table 2-2. siRNA sequences for mESC treatment. Sequences were not made
available with purchase.
siRNA
Target Region
mDax-1 siRNA 1

Exon 1, Position 981

mDax-1 siRNA 2

Exon 1, Position 1187

mDax-1 siRNA 3

Exon 1, Position 987

CRISPR-mediated knock-down in E14 mESC
pSpCas9(BB)-2A-Puro (PX459) plasmid was purchased from Addgene
(plasmid # 48139). The structure of the plasmid along with key features is
illustrated in Figure 2-4. Oligonucleotides for insertion into the CRISPR-Cas9
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vector backbone to target mouse DAX1 were designed using the online
CRISPR Design web program (http://crispr.mit.edu/). Target areas for each
guide are shown in Figures 2-5 and 2-6, with sense and antisense sequences
listed in Table 2-3. Annealed oligonucleotides were inserted into the pX459
plasmid using BbsI as the restriction enzyme to cut the insertion site and T4
DNA ligase (New England Biolabs). Proper insertion of the guide sequences
into the plasmid backbone was verified through both a BbsI/AgeI double
digest, based on the restriction enzyme target sites illustrated in Figure 2-4B,
as well as DNA sequencing using a U6 primer (MCLAB, Molecular Cloning
Laboratories). Modified plasmids with successful insertions were
transformed into competent DH5 E. coli (New England Biolabs) and plasmid
DNA was extracted using the Plasmid Plus Maxi kit (Qiagen). Complete
pX459 with oligonucleotide insertions were transfected into mESCs using
Lafectine RU50 1000ng/μL according to the product protocol using reduced
media (Dulbecco’s Modified Eagle Medium (DMEM) with phenol red; 10%
FBS, LIF, β-mercaptoethanol). Cells were treated for 48 hours before
selection with 1.0 μg puromycin. Treatment with puromyin was sustained for
48 hours before surviving cells were collected and recovered in normal
media. Individual colonies were picked in parallel to grow out individual
transfected cells and obtain clonal populations for further analysis [40].
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A.

B.

Figure 2-4. Structure summary of the CRISPR-Cas9 optimized plasmid pX459.
A. Overall pX459 structure provided by Addgene. B. Details of BbsI restriction
enzyme sites for insertion of a designed guide sequence for CRISPR-Cas9 targeting.
Figure provided by Zhang lab.
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Table 2-3. Sense and anti-sense sequences for oligonucleotides constructed
using the online CRISPR Design web program to target the Dax-1 gene.
Guid Sense
Anti-sense
Targ Color
e
et
Code
Nam
Exon
e
G3
caccGGGTGAGGACCACCCGT aaacGCCACGGGTGGTCCTCA Exon green
GGC
CCC
1
G6
caccGCTGAGATTCATCAATA aaacCGCTATTGATGAATCTC Exon pink
GCG
AGC
2
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agtttataaagctgtcatagaaatggactttttgccatttaagcatttctttccccaataaaggaaataagttagaggtcaga
gtctaagttaatggcaagagttggaacagagccctaactagctgcctggggttcactgctagctcttctcttccccaggtag
aggcaggaggggtggagtgaagaaggaaaggtggtatgtggtatgctagttccagtgctgagactctcccttggatttcc
agcttctagggagtgtttgcccctttgagctttcgaggtcatggccacacacattcaagcacaaaggcgcgtccccctctgc
gcccttgtccaagaggaggaggcggacgcgcttgcgtgcgcattcagtataaataagtcccaagcggcggccactgggc
AGAACGAGCTACAGGAGCCTCAGGCCATGGCGGGTGAGGACCACCCGTGGCAGGGCAG
CATCCTCTACAATCTACTGATGAGCGCGAAGCAGAAGCACGCGTCTCAGGAAGAGCG
AGAGGTGCGCTTGGGGGCTCAGTGCTGGGGTTGCGCCTGCGGTGCTCAGCCCGTCCT
GGGTGGGGAGAGACTGTCCGGCGGGCAAGCCAGGTCCCTCTTGTACCGCTGCTGCTT
TTGTGGGGAGAATCACCCGCGCCAGGGTGGCATCCTCTACTCTATGCTCACCAACGC
CAGGCAGCCAAGCGTGGCGACCCAGGCGCCGAGGGCACGATTCGGAGCACCTTGCTG
GGGCTGCGCCTGCGGCAGCGCAGAGCCCCTGGTGGGCAGAGAGGGGCTGCCGGCTGG
CCAGGCCCCCTCGCTCCTGTACCGCTGCTGCTTCTGCGGAGAAGAGCACCCGAGGCAG
GGCAGCATCTTATACAGCTTGCTCACTAGCGCTCAGCAAACGCACGTGTCTCGGGAA
GCACCCGAGGCACATCGCAGAGGCGAGTGGTGGCAGCTGTCCTACTGTACCCAGAGT
GTGGGTGGCCCAGAGGGGCTGCAGAGCACACAGGCCATGGCGTTCCTGTACCGCAGC
TATGTGTGCGGTGAAGAGCAGCCCCAGCAGATCAGCGTTGCCTCTGGCACGCCCGTG
AGCGCAGACCAAACACCAGCGACCCCGCAAGAGCAGCCGAGGGCTCCCTGGTGGGAC
GCCTCACCTGGTGTGCAGCGTCTGATCACACTCAAGGATCCACAGGTGGTGTGCGAG
GCAGCGTCCGCTGGCCTGTTGAAGACCCTGCGCTTTGTCAAGTACTTGCCCTGCTTCC
AGATCCTGCCCCTAGATCAGCAGCTGGTGCTGGTGCGGAGCTGTTGGGCGCCCCTAC
TCATGCTTGAGTTGGCCCAAGATCACCTGCACTTCGAGATGATGGAGATCCCGGAGA
CCAACACGACGCAGGAAATGCTTACCACCAGGCGGCAGGAGACCGAAGGTCCAGAGC
CTGCAGAGCCCCAGGCCACAGAGCAGCCACAGATGGTGTCCGCGGAGGCTGGGCACT
TGCTCCCAGCTGCTGCGGTCCAGGCCATCAAGAGTTTCTTTTTCAAGTGCTGGAGTC
TGAACATTGACACCAAAGAGTATGCCTATCTGAAAGGGACCGTGCTCTTTAACCCAG
gtaagcattgtcaaccttgtgcactgtctcttcaggtcagaaaagcaccactacagacatttatgagtttttagtaggggttt
tggagcccacttgactgtgactgactctgcaaatctgctgcacacatcaggaataccctgtcaagtggtcaaatgggtgag
cttctgccagaaacttggcactggattggtggtgatagtgtgtgtgtgtggggggggggggggcaggggttggggggag
ggtggggaacgaaccagtaagctttgtacctggctctctattatctgctgctacagaagtttctgtcttcataggacctggct
aactcttc
Figure 2-5. CRISPR targets within the Dax-1 gene (first exon). Sequence of the
first exon of the Dax-1 gene, with CRISPR targets for guide 3, highlighted green and
underlined. Intron/non-coding nucleotides are in lowercase, and exon/coding
regions are in uppercase.
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tattaagtgtgccagtgtttgtgcacactttagtgtgtccagtgtatgtgcacacatcctttcatccttagaagtgttgcttctg
aaaacttagaacttatttcagtccattattttaggccccagaaaacccttttaatcaagaagctagggttctttttaatcggg
atgggactaaaaaaaatgagtttggcctaaaccataaagatcctgtggtgagctgttttaaaataaagttttctcctttcag
ACCTGCCTGGCCTGCAGTGCGTGAAATACATTGAGGGTCTTCAGTGGAGAACCCAGC
AGATCCTTACTGAGCACATCCGGATGATGCAGAGAGAGTACCAGATCAGATCCGCTG
AACTGAACAGTGCCCTTTTCCTGCTGAGATTCATCAATAGCGATGTCGTCACTGAACT
CTTTTTCAGGCCCATCATTGGTGCAGTCAGCATGGATGATATGATGCTGGAGATGCT
CTGTGCAAAGCTGTGAAGGCATATGTCCACTCAAGTGCATTTTACTATAGATGGAG
AAAGCGGTCGTAGCTGTAGGCAGAAGAGTGCTAAAATTTGTGAAACCAAACTTTCT
TGTATTTTTACATGCATAGTATATTTGTATTCAATTGAAGAAATACTTTAGTTACA
ATGTAAAAATCCCTCTGCTCCATACTGGCTTCTTGTGAAGGAAAGCATTTGCAAACA
AATCACTATTTCTGTATATCTCTAAGAGTGTGGTACTAGGCTAACAAGCTAATTTC
ATAAAAATAACATCTCTTTCCATTAACCCCGCCAAATAAAATTTATAATATTAACTT
TTAATAAAATTTAAGGTACTAACCGTTaaacggactggagagttttcttggggtttacagcttcaaata
ctttcaaatctagctaaaataactgaagatacaatcgtgagtaacttcatggaatttaatgctacagtatgtcactggttaa
aaaaaaaaaaaggttattttgcctggcttcactgcttccattaacagtataaaagattgtcttcattcctgcctggaactcaa

Figure 2-6. CRISPR targets within the Dax-1 gene (second exon). Sequence of the
second exon of the DAX1 gene, with the target for guide 6 (G6) underlined, in italics,
and in pink. Intron/non-coding nucleotides are in lowercase, and exon/coding
regions are in uppercase.
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Results
MCF7 breast cancer cells were successfully treated to express DAX-1, as
verified by both standard PCR run through an agarose gel (Figure 2-7A) and
quantitative PCR analysis (Figure 2-7B). Knock-in expression was nearly four times
the relative untreated expression when normalized with GAPDH using delta Cq
calculations, and was considered to be statistically significant with a p-value less
then 0.001. These samples were used for further analysis in Chapter 3.
MCF10A cells experienced a reduction in DAX-1 mRNA expression with
siRNA treatment using the three transcripts listed in Table 2-1, as verified by
standard PCR in agarose gel (Figure 2-8A) and quantitative PCR (Figure 2-8B).
Relative expression was reduced to negligible amounts through delta Cq
calculations and was statistically significant with a p-value of less than 0.005. These
samples were used for further analysis in Chapter 3.
Mouse embryonic stem cells were treated with both siRNA and CRISPR-Cas9
methods to knock-down endogenous expression of Dax-1. The transient knockdown of Dax-1 expression using siRNA transcripts listed in Table 2-2 was verified
through agarose gel electrophoresis of standard PCR samples (Figure 2-9A),
quantitative PCR analysis (Figure 2-9B), and western blotting (Figure 2-9C). Using
two concentrations of siRNA treatment, the cells treated with 20 pmol and 80 pmol
of siRNA each experienced a knock-down to half the normal expression when
compared to untreated and Scramble/negative control (NC) cells. Both values were
statistically significant when compared to the untreated and negative control, with
the 20 pmol sample having a p-value of less than 0.005 and the 80 pmol sample
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having a p-value less than 0.001. These samples were used for further analysis in
Chapter 4.
Development of a pX459 plasmid complete with an inserted guide for Dax-1
CRISPR-Cas9 knock-down in mESC is shown in Figure 2-10. Based on the design of
the insertion site (Figure 2-4B), successful insertion of a guide sequence results in
the loss of the BbsI restriction enzyme target site. Comparison of a complete
plasmid with insertion and one with no insertion is shown in Figure 2-10A. Loss of
the BbsI site results in a single linear product when digested with both BbsI and
AgeI. However, lack of an insertion preserves the BbsI site resulting in two
fragments, including a 1,000 base pair fragment (detectable in Figure 2-10A).
Initially, the six guides, illustrated in Figures 2-5 and 2-6 and listed in Table
2-3, were screened for proper insertion. Out of the six, guide 3 and 6 passed the
double digest screen and showed no 1kb dropout fragment, and were subsequently
verified by DNA sequence analysis (Figure2-10A and B). Following transfection with
the verified plasmids and puromycin screening, several individual mESC colonies
that survived treatment were isolated. Whole flask samples (labeled with the letter
A) and isolated colonies (labeled from 1 to 10) were used for further Dax-1 knockdown verification from the two treatments of G3 and G6 CRISPR-Cas9 guides that
were selected for. These were tested using standard PCR in agarose gel (Figure 211A), quantitative PCR (Figure 2-11B), and western blots (Figure 2-11C). Based on
the results, isolates G3-1 and G6-1 were used for further analysis in Chapter 4.
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A.

B.

Figure 2-7. Introduction of DAX-1 expression in MCF7 cells by transient
transfection with pCDNA DAX-1. A. Agarose gel electrophoresis of PCR samples
comparing DAX-1 expression in untreated and transfected samples (GAPDH is
shown as a positive control). B. qPCR results comparing the relative expression of
DAX-1 mRNA in untreated and transfected cells. Error bars on qPCR results
represent standard deviation of the mean.
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A.

B.

Figure 2-8. siRNA DAX-1 knock-down in MCF10A. A. Agarose gel electrophoresis
of PCR samples comparing DAX-1 amounts in untreated and transfected samples
(GAPDH is shown as a positive control). B. qPCR results comparing the relative
expression of DAX-1 mRNA in untreated and transfected cells. Error bars on qPCR
results represent standard deviation of the mean.
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A.

B.

C.

Figure 2-9. siRNA Dax-1 knock-down in mESC. A. Agarose gel electrophoresis of
PCR samples comparing Dax-1 amounts in untreated and transfected samples
(GAPDH is shown as a positive control). B. qPCR results comparing the relative
expression of Dax-1 mRNA in untreated and transfected cells. Error bars on qPCR
results represent standard deviation of the mean. C. Western blot of Dax-1 protein
expression in untreated and transfected mESC. GAPDH protein expression is
included as a loading control.
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A.

B.

C.
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Figure 2-10. Dax-1 specific CRISPR-Cas9 construct design. A. Screen cloned
samples for proper insertion through a double digest with restriction enzymes AgeI
and BbsI. The guide insertion site has BbsI target sites, so without an insert, a
double digest will show a 1kb fragment. With guide sequence insertion, loss of the
BbsI target site will lead to a single cut at the AgeI site and result in a linear product
around 9kb length. B. Sequencing results verifying guide sequence insertion
(highlighted in grey) in a guide 3 sample. C. Sequencing results verifying guide
sequence insertion (highlighted in grey) in a guide 6 sample.
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A.

B.

C.

Figure 2-11. CRISPR Dax-1 knock-down in mESC. A. Agarose gel of PCR samples
comparing Dax-1 amounts in untreated and treated G3 and G6 samples (guide
targets illustrated in Figure 2-5 and 2-6) with GAPDH as a positive control, B. qPCR
results comparing the relative expression of Dax-1 mRNA in untreated and G3 and
G6 transfected cells. Error bars on qPCR results represent standard deviation of the
mean. C. Western blot analysis of Dax-1 protein expression in untreated and G3 and
G6 transfected cells. GAPDH is included as a loading control.
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Discussion
The successful treatment of the human cell lines MCF7, with the introduction of
DAX-1 expression through a pcDNA3.1 vector, and MCF10A , with the knock-down
of DAX-1 expression through siRNA, was carried out to see the effect of mirrored
DAX-1 modification in the same cellular background yet with different endogenous
DAX-1 expression levels. This system allows for subsequent analysis of downstream
targets within specific pathways in Chapter 3.
The treatment of E14 mESC with both siRNA and CRISPR-Cas9 allowed for two
different methods with the same outcome – knock-down expression of endogenous
Dax-1. Unlike the human mammary epithelial cell model, there is no variation in
wild-type stem cells and Dax-1 is endogenously expressed in relatively high
amounts. Each method uses different mechanisms for knocking down gene
expression, and using both will allow any possible off-target effects of an individual
method to be disregarded. The results of these treatments to mESC are used for
subsequent analysis of candidate Dax-1 target genes in relation to pluripotency in
Chapter 4.
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Chapter 3
DAX-1 Mediates Expression of Apoptosis-Inducing Genes in Human Breast
Cancer
Introduction
Amongst the various human diseases, cancer poses a great threat to the human
population. As the life expectancy rises, so does the risk of cells functioning
abnormally within the human body. The umbrella term of cancer mistakenly
simplifies the complexity of the disease as a whole, which affects nearly every type
of cell. It is expected that there will be about 1.5 million new diagnosed cases in the
United States in 2015. Estimates for 2015 in the United States alone put breast
cancer as the second leading cause of cancer death for women, with about 40,000
expected cancer deaths (Figure 3-1). Research of specific types of cancer is made
possible with cell culturing of commercially available cell lines, such as MCF7 [41],
that are well characterized and give great insight into the mechanisms and changes
that contribute to onset and persistence of cancer.
An early study linking DAX-1 to androgen receptor activity in human breast
cancer cells saw a significant decline in cell proliferation with the introduction of
exogenous DAX-1 into MCF7 [42]. Additionally, experiments in the TzagarakisFoster lab brought to light the connection of DAX-1 to the decline of cell survival.
Studies within our lab have confirmed that DAX-1 affects cell growth and survival
from the aspect of proliferation through interaction with estrogen receptor, cyclin D,
and Ki-67 [43]. Results from cell proliferation assays not only showed a decline in
growth rate, but an overall decrease in cell population (Tzagarakis-Foster et al,
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unpublished), indicating that cell death is another cause of the decline of survival as
well. If DAX-1 was to be involved as a transcription factor with this cellular process,
it is likely that it contributes to apoptosis, or programmed cell death.
Results observed in MCF7 cells prompted further investigation in an opposing
model system with DAX-1 highly and endogenously expressed. The lung
adenocarcinoma cell line A549 was treated with siRNA to knock-down DAX-1
expression, and the treated cells were compared with untreated cells in an
apoptosis PCR array (Nguyen and Tzagarakis-Foster, unpublished). Analysis and
comparison of the gene expression of the genes (Figure 3-2) provided in the array
allowed for the selection of candidate DAX-1 targets that work within known cell
death pathways. Candidate genes that had demonstrated a fold-change, either
decrease or increase, greater than two-fold were selected for further analysis. The
number of genes that showed a change in expression with knock-down further
confirmed a strong degree of DAX-1 influence on apoptosis.
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Figure 3-1. Estimated Cancer Deaths in the US (Cancer Facts and Figures 2015,
American Cancer Society).
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Figure 3-2. Workflow of PCR Array (SABiosciences). Comparison of an untreated
and treated sample is done by running individual plates and measuring relative
expression of candidate genes, then calculating the fold change difference between
samples.
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Apoptosis is an efficient way for an organism to maintain tissue homeostasis and
to clear old or aberrant cells. [44]. Evading apoptosis is one of the chief hallmarks of
cancer [45]. Altering major apoptotic pathways gives cancerous cells an advantage
over natural and artificial stressors that typically activate a cell death cascade. The
cellular pathways that lead to cell death can be described as either extrinsic or
intrinsic. Extrinsic programming is caused by extracellular death ligands
interactions with transmembrane protein receptors. Intrinsic programming is
triggered by intracellular signals, such as elevated oncogene signaling and DNA
damage, or upstream activity from extrinsic signaling pathways. While these
pathways differ in their different specific molecular targets, they converge and lead
to morphological changes within the cell as it begins to die. Cells going through early
apoptosis can be identified through light microscopy by their characteristic
shrinkage and visible chromatin condensation. When going through the later stages
of apoptosis, the plasma membrane separates from the cytoskeleton causing the cell
to start blebbing, organelles get fragmented into apoptotic bodies, and the dead cell
is then consumed by macrophages through phagocytosis [44].
The breakdown of internal materials can be categorized into two pathways,
distinguished by the use of caspases. The caspase-independent Granzyme A
pathway is carried out through single-stranded DNA damage [46]. The more
common pathway depends on caspases, the shortened name of cysteine-aspartic
proteases, that are generally present as inactive proenzymes in a living, active cell
[47]. Among the twelve known caspases, five are clearly involved with apoptosis.
The five caspases are subcategorized by their mechanism of action: caspases 8 and 9
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are initiators while caspases 3, 6, and 7 are executioners [48]. Once activated, these
enzymes cleave proteins at aspartic acid residues, with each one specific depending
on the neighboring amino acids [49] [50]. The inactivation and degradation of key
proteins leads to the breakdown of internal components, and eventual breakdown
of DNA through CAD, or caspase-activated DNase [51].
The results from the knock-down of DAX-1 saw a change in expression of genes
that fell within two major apoptotic, caspase-dependent pathways. The first
category fell under the TNFα pathway, an extrinsic pathway that influences both cell
proliferation and apoptosis. The TNFα ligand interacts with two receptors: TNFR-1,
also known as p55, and TNFR-2, also known as p75. TNFR-1 mediates most
apoptotic signaling [41], as seen in Figure 3-3, while TNFR-2 is upstream of antiapoptotic, cell proliferative, and cell survival signals such as NF-κB [52]. Upon
interaction of the ligand with a death receptor like TNFR-1, the cytoplasmic “death
domain” of the extracellular receptor recruits adapter proteins such as TRADD,
FADD, and RIP. This recruitment associates with procaspase-8, resulting in the
activation into caspase-8 and leading to downstream apoptotic effects [53].
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Figure 3-3. TNFα pathway, with the major interactions leading to either cell
proliferation or apoptosis through the triggering of the caspase cascade.

53

The second general category of genes that saw a change in expression in
response to reduced DAX-1 was the BCL-2 family. This is a major intrinsic pathway,
illustrated in Figure 3-4, that is strongly linked to programmed cell death, and is a
major target for therapy due to its sole involvement with apoptosis alone [54].
There are three categories of proteins based on function and structure. Four distinct
domains within the BCL-2 family, ranging from BH1 to 4, relate to their interactions
with one another [55]. The first, most upstream members of the BCL-2 family are
the BH3-only domain proteins. These proteins, such as BNIP3 and BID, are only able
to interact with isoforms of BCL-2 [56]. By inhibiting anti-apoptotic members of
BCL-2 and activating pro-apoptotic members, BH3-only proteins cause
mitochondrial outer membrane permeabilization (MOMP), which releases internal
proteins of the mitochondria and leads to the caspase cascade described earlier
[57].
As mentioned earlier, while these two categories are distinct, they ultimately
converge to result in the outcome of cell death. There is some crosstalk between the
two different pathways when deciding on the activation of caspases. Ultimately, the
genes were investigated by organizing them based on their function, rather than by
protein family. The genes analyzed that inhibit apoptosis when expressed, or antiapoptotic genes, are listed in Table 3-1, while genes that function to promote
apoptosis, or pro-apoptotic genes, are listed in Table 3-2.
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Figure 3-4. BCL-2 family apoptosis pathway. BH3-only proteins like BNIP3
and BID are able to activate BAX and BAK proteins to cause membrane
permeabilization of the mitochondria and release internal components like
cytochrome c that cause activation of caspases.
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Table 3-1. Anti-apoptotic candidate target genes.
Gene Name

Function

TNFα

Encodes a protein that is a death receptor ligand; when it binds to
TNFR2, activates both cell proliferation and apoptotic pathways
downstream [52]
Encodes a death domain containing protein that suppresses
TRAF2 recruitment of inhibitor-of-apoptosis proteins (IAPs) [58],
but also has anti-apoptotic function because of influence on NFκB
[59]
Encodes a protein that associates with TRAF2 to form a complex
needed to activate NFκB and activate IAPs [58]
Large isoform of BCL-2, encodes a transmembrane protein that is
present in the mitochondria, prevents the release of cytochrome c
[56]
Isoform of BCL-2 that prevents the release of cytochrome c [56]
Isoform of BCL-2 that prevents the release of cytochrome c [56]
Isoform of BCL-2 that prevents release of cytochrome c [56]

TRADD

TRAF1
BCL-XL
BCL-L2
BCL2-A1
BCL-L10
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Table 3-2. Pro-apoptotic candidate target genes.
Gene Name

Function

BCL-XS

The shorter isoform of BCL-2 that acts as an apoptotic activator
by allowing for the release of cytochrome c [56]

BCL2-L1

One of the smaller isoforms of BCL-2 that allows for the release of
cytochrome c [56]
A BH1 through 3 domain containing protein that associated with
the membrane to release cytochrome c [56]
A BH3-only protein that forms a heterodimer with anti-apoptotic
proteins to prevent the inhibition of apoptosis [56]
Activates the immune response and contributes to the
lymphotoxin-beta receptor signaling complex, which induces
NFκB activation and cell death [58]

BAX
BAD
TRAF3
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Methodology
While the changes in the gene expression in the mentioned pathways were
significant enough to suggest some influence, some sort of measurement of the
actual occurrence of apoptosis with DAX-1 presence is required to confidently
associate DAX-1 with apoptosis. Annexin V and propidium iodide staining can be
used to quantify cells undergoing apoptosis through cell flow cytometry. During
early apoptosis, the membrane protein phosphatidylserine is flipped to the exterior
of the cell, which allows for Annexin V to bind and tag a cell. As a cell progresses
through the breakdown of internal components, DNA is more readily accessible and
stained by propidium iodide (Figure 3-5A). Cell flow cytometry allows for the
comparison of the degree of staining with these two reagents to identify and
characterize cells within a population sample (Figure 3-5B).
If a candidate gene displays a mirrored change in expression with changes in
the amount of DAX-1 presence, chromatin immunoprecipitation (ChIP) is an assay
that can be used to test for the presence of DAX-1 within the regulatory region of the
target gene. One form of this technique, called X-ChIP, crosslinks proteins attached
to DNA. With the proteins locked onto the genome, cells are lysed and the chromatin
is sheared through sonication into smaller fragments for easier analysis. The target
protein, still attached to DNA, is selected using antibodies or any other method
specific to the protein. The DNA and proteins are then separated, and the fragments
of DNA are used for further analysis (Figure 3-6).
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A.

B.

Figure 3-5. Annexin V and PI staining of apoptotic cells. A. The attachment of
the dyes Annexin V-FITC and propodium iodide (PI) depend on the accessibility of
the membrane protein phosphatidylserine (PS) and chromatin, respectively. Cells
that are going through early apoptosis will have PS flipped outwardly, and cells
going through late apoptosis or necrotic cells will also have chromatin readily
stained with PI due to breakdown of the nucleus. B. Quantification of cells based on
the amount of staining of both reagents is carried out by cell flow cytometry and
graphed on the computer.
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Figure 3-6. Workflow of X-ChIP Assay (AbCam). Untreated or treated cells are
treated with formaldehyde in order to leave proteins in contact with genomic DNA
to stay attached. Cells are then lysed and the chromatin is sheared to 300 to 500
base pair fragments. Antibodies are added, and samples are immunoprecipitated to
isolate the fragments with protein(s) of interest. Proteins are released and the
remaining DNA fragments are purified for downstream analysis.
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Materials and Methods
RNA and cDNA extraction
MCF7 human breast cancer cells and MCF10A human normal breast cells,
untreated and treated as stated in Chapter 2, were lysed and messenger RNA
was collected using QIAGEN RNeasy Kit according to the manufacturer’s
protocol. Nucleic acid concentrations were measured using the GE Nanovue
Plus Spectrophotometer. Complementary DNA (cDNA) was then synthesized
from 1 μg of collected mRNA using various kits (High Capacity cDNA Reverse
Transcription Kit from Applied Biosystems; M-MuLV Reverse Transcriptase
from New England Biolabs; QuantiTect Reverse Transcription Kit from
QIAGEN) according to the corresponding protocol.

Small Molecule Inhibitor
BADGE (Bisphenol A diglycidyl ether; 2,2'-[(1-Methylethylidene)bis(4,1phenyleneoxymethylene)]bis-oxirane), a TNFα inhibitor that is known to
induce apoptosis in tumor cells, was prepared to a working concentration of
1 mM in 100% ethanol from the stock (Santa Cruz Biotech, cat no. sc202487). 100 μL was used in each well of a twelve-well plate. Cells were
treated for 48 hours before collection and flow cytometry analysis.

Flow Cytometry
MCF7 cells were plated in twelve-well dishes and either untreated,
transfected with pcDNA-DAX-1 as stated in Chapter 2, treated with BADGE
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alone, or BADGE and pcDNA-DAX-1. After collection, each treatment of cells
was left unstained, stained with Annexin V alone, stained with PI alone, or
stained with the combination of Annexin V and PI. Cells were quantified
using the BD Accuri C6 Cytometer and its provided computer program, with
a sample size of 10,000 cells per reading.

Polymerase Chain Reaction (PCR)
Annealing temperatures were optimized using Promega GoTaq Green Master
Mix. Primers listed in Table 3-5 and any subsequent primers used were all
ordered from Integrated DNA Technologies. Conditions in Table 3-3 were
used, with optimized annealing temperatures for specific primer pairs used
for step 3. Upon completion, samples were removed from the 4°C hold and
stored until further analysis.

Table 3-3. Thermocycler conditions and steps for standard PCR.
Step

Temperature

Time

1

95°C

5 minutes

2

95°C

30 seconds

3

53-60°C

30 seconds

4

72°C

30 seconds

5

Repeat steps 2 to 4 x thirty times

6

4°C

∞
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Real-Time PCR (qPCR)
Quantitative PCR analysis was performed on untreated and treated cDNA
collected from MCF7 and MCF10A cells to analyze the relative gene
expressions of target genes, normalized with GAPDH expression. SYBR green
master mixes (BioRad and QIAGEN) and the respective primer pairs for the
genes listed in Table 3-5 were used for apoptotic gene analysis. Primers with
a source as “construct” were designed using NCBI Primer-BLAST using the
available cDNA sequences online. Each sample was prepared using 10 μL of
SYBR green master mix, 0.25 μL of the forward primer, 0.25 μL of the reverse
primer, 7.5 μL nuclease free water, and 2 μL of cDNA. All samples were run in
triplicate for 40 cycles using the two-step amplification program, outlined in
Table 3-4, with the BioRad CFX96 Touch Real-Time PCR Detection System.
Results were analyzed using the BioRad CFX Manager™ software and
Microsoft Excel.

Table 3-4. Thermocycler conditions and steps in the two-step amplification
program for qPCR. Fluorescent dye detection occurred at step 3.
Step

Temperature

Time

1

95°C

5 minutes

2

95°C

30 seconds

3

55-60°C

15 seconds

4

Repeat steps 2 and 3 x thirty-nine times
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Statistical Anaylsis
Data from the qPCR analysis are presented with the mean + standard
deviation of triplicate experiments. Statistical significance is calculated in the
same manner described in Chapter 2.

Table 3-5. Primers used for apoptosis qPCR analysis.
Gene

FWD

REV

Source

TNFα
TRAF2

GGAGAAGGGTGACCGACTCA
TGGCTGGCCGCATACC

Construct
Construct

TNFR1
TNFR2

TACATTGCAGCCTCTGCCTC
ACATCAGACGTGGTGGTGCA
A
AGCTCATAGTGAACCGGCCA
CTGCACCTGACGCCCTTCAC
C
GATCCCCATGGCAGCAGTAA
AGCAAG
ATGGAGCTGCAGAGGATGAT
T
GCCTTCATTTATCTCTGGAC
ACG
CCCGGATGTGGATACCTATA
AGGAGA
GACAGGGAGCTGGTTCACAT

CTGCCCAGACTCGGCAA
TGTAGCCGTACCTGCTGGTG
TA
AGAGCTTGGACTTCCACCGT
CCAACTGGAAGAGCCAAGTC
TCCCTCAGTGCTCGACAGC
CACATGACCCCACCGAACTC
AAAGA
CCCCATCCCGGAAGAGTTCA
TTCACT
TGAAGTTGCCATCAGCAAAC
A
GAAGGTGCTTTCCCTCAGTT
CTT
GTCATCCAGCCAGATTTAGG
TTCA
AGGATCTCTAGCCAGGCACA

Construct
Construct

TRADD
BCL-XS
BCL-XL
BAX
BCL2-L10
BCL2A1
ERα

Construct
[59]

Construct
Construct
Construct
Construct
Construct
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Western Blot
Protein lysates were collected from untreated and treated cells grown in six
well plates according to protocol using M-PER Mammalian Protein Extraction
Reagent (Thermo Scientific). Protein concentrations of collected cell lysates
were determined by Bradford Protein Assay using a bovine serum albumin
(BSA) dilution standard. Lysates normalized to 10,000 ng total per well were
prepared for SDS-PAGE gel electrophoresis using Novex NuPage LDS and
Reducing Agent (Thermo Scientific). Samples were electrophoresed through
a NuPage 4-12% Bis-Tris precast gel at 200 V for 45 minutes in 1X MOPS
running buffer and then transferred onto a PVDF membrane in NuPage
Transfer buffer with 20% methanol. The PVDF membrane(s) were blocked
in 5-10% Blotto in TBST prior to incubation with appropriate antibodies
(Santa Cruz Biotechnology, Inc. and ActiveMotif) as listed on Table 3-6 in a
1:1000 dilution in Blotto. Blots were then treated with secondary mouse or
rabbit antibodies based on the host of the primary antibodies diluted 1:2000
in 5% Blotto in TBST. Protein bands were developed using the Clarity ECL
Western Blotting substrate kit (BioRad) according to protocol and visualized
using a BioRad Gel Doc™ XR+ System with the ImageLab software.
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Table 3-6. Monoclonal Antibodies used for Western Blotting.
Protein Target

Host Organism

Cat. No, Company

Beta-Actin

Mouse

sc-82278, Santa Cruz

GAPDH

Rabbit

3683, Cell Signaling

DAX-1

Mouse

39983, ActiveMotif

BCL-2 (XL isoform)

Rabbit

GTX127958, GeneTex

BAX

Rabbit

GTX109683, GeneTex

66

Chromatin Immunoprecipitation (ChIP)
MCF7+DAX1 cells were collected for treatment using the AbCam 500 ChIP kit
according to protocol. Antibodies for the protein targets listed in Table 3-7
were used. Primers used to analyze the promoter regions of two possible
targets, broken down into individual regions (Figure 3-7) were designed
using NCBI’s Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primerblast/) and are shown in Table 3-8.
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A.

B.

Figure 3-7. Targeted regions of the A. BCL-2 and B. BAX promoter. Each region
has an individual length of about 200 to 300 base pairs.
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Table 3-7. Antibodies used for ChIP assay.
Protein Target
Host Organism

Cat. No, Company

Histone H3

Rabbit (polyclonal)

1791, AbCam

DAX-1

Mouse (monoclonal)

39983, ActiveMotif

ERα

Rabbit (polyclonal)

GTX100634, GeneTex

Table 3-8. Primer sets corresponding to promoter regions of BCL-2 and BAX.
Gene
BCL-2
BAX

Region
Region 3
Region 4
Region 1
Region 2

FWD
CCCCTCGTCCAAGAATGCAA
ACGCCCCATCCAGCCG
GGGTGGCTCAAGCCTGTAATC
GAGCCATGATTGGGCCACTG

REV
CATCTCCCGCATCCCACTC
CCCGCGCGGTGAAGG
GAGTGCAGTGGCCCAATCAT
CCAGGCAGGACGTTATAGAT
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Results
Introduction of DAX-1 increases number of apoptotic cells in population
Cell flow cytometry was used to quantify the number of early and late
apoptotic cells. The number of cells that fell in the right hand quadrants in Figure 34A were quantified in Figure3-4B. There was a significant increase of apoptotic cells
in the MCF7-DAX-1 samples, specifically from 1.3% to 23.2%. Cells treated with
BADGE alone saw a similar significant increase from 1.3% to 29.7%. There was no
significant difference between singular treatment of BADGE or pcDNA-DAX-1 alone
compared to BADGE and pcDNA-DAX-1 (31.3%) in combination.
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A.

B.
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Figure 3-8. Cell flow cytometry of Annevin V and propidium iodide stained
MCF7 cells untreated and treated with pcDNA-DAX1. A. Contour diagram of
FITC-Annexin V/PI flowcytometry of MCF7 calls after 48 hour collection following
transfection with pcDNA-DAX-1, and either no treatment or treatment with BADGE,
or untransfected (UT) cells. B. Quantification of the right-hand quadrants from each
cell flow cytometry sample to give value to the number of apoptotic cells with or
without treatment. Error bars shown represent 5% error of shown value.
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Changes in candidate genes within MCF10A DAX-1 knock-down cells
MCF10A cells that underwent siRNA treatment in order to transiently knockdown DAX-1 expression, treated as stated in Chapter 2, were lysed for collection of
mRNA. Complementary DNA synthesized from the collected mRNA of treated and
untreated cells were then analyzed by qPCR to compare gene expression changes.
Among the anti-apoptotic candidate genes that were analyzed (Figure 3-9), BCL-L2
(A), BCL-XL (B), TNFα (D), and TRADD (G) increased in expression, while BCL2-A1
(C), TRAF1 (E), and BCL-L10 (F) decreased in expression. For the pro-apoptotic
genes that were analyzed (Figure 3-10 A-E), BAX, BAD, BCL-XS, BCL-L1, and TRAF3
all showed varied degrees of significant decreased expression.
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A.

B.

C.

D.

74

E.

F.

G.

Figure 3-9. qPCR results of anti-apoptotic candidate genes tested in MCF10A
knock-down total mRNA samples. Relative expression values were normalized
using the expression of GAPDH to compare treated siRNA knock-down samples to
untreated samples. Results shown correspond to candidate genes A. BCL-L2, B. BCLXL, C. BCL2-A1, D. TNFα, E. TRAF1, F. BCL-L10, and G. TRADD. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that
were p<0.005, and a triple asterisk (***) represents samples that were p<0.001.
Error bars on qPCR results represent standard deviation of the mean.
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A.

B.

C.

D.
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E.

Figure 3-10. qPCR results of pro-apoptotic candidate genes tested in MCF10A
knock-down total mRNA samples. Results shown correspond to the candidate
genes A. BAX, B. BAD, C. BCL-XS, D. BCL-L1, and E. TRAF3. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that
were p<0.005, and a triple asterisk (***) represents samples that were p<0.001.
Error bars on qPCR results represent standard deviation of the mean.
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Changes in candidate genes within MCF7 pcDNA-DAX-1 cells
The cDNA synthesized from collected mRNA of MCF7 cells, treated as
described in Chapter 2 to express DAX-1, was analyzed by qPCR to compare gene
expression changes of specific candidate genes. The gene expression of antiapoptotic gene candidates BCL-XL, TRAF1, and TRADD (Figure 3-11 A, C, D) showed
a significant decrease in expression with DAX-1 treatment , while BCL-L2 (Figure 311B) saw slight decrease but was not statistically significant. Of the pro-apoptotic
genes analyzed (Figure 3-12), BAX (A) saw a significant increase in expression,
while BCL-XS (C) and TNFR1 (F) saw a significant decrease. The genes BAD (B),
BCL2-L1 (D), and TRAF3 (E) also saw a decrease in expression, but were not
statistically significant.

78

A.

B.

C.

D.

Figure 3-11. qPCR results of anti-apoptotic candidate genes tested in MCF7
knock-down total mRNA samples. Results shown correspond to the A. BCL-XL, B.
BCL-L2, C. TRAF1, and D. TRADD genes. A single asterisk (*) represents samples that
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR
results represent standard deviation of the mean.
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A.

B.

C.

D.
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E.

F.

Figure 3-12. qPCR results of pro-apoptotic candidate genes tested in MCF7
knock-down total mRNA samples for candidate genes A. BAX, B. BAD, C. BCL-XS,
D. BCL2-L1, E. TRAF3, and F. TNFR1. A single asterisk (*) represents samples that
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR
results represent standard deviation of the mean.
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Selected genes further analyzed for expression changes reflected in protein expression
The genes BAX (Figure 3-10A and Figure 3-12A), the large BCL-2 isoform
BCL-XL (Figure 3-9B and Figure 3-11A), and TRADD (Figure 3-9G and Figure 3-11D)
were observed to have significant mirrored expression with the opposing DAX-1
expression models, as listed in Table 3-9. BAX, a pro-apoptotic protein, and BCL-XL,
an anti-apoptotic isoform of the BCL-2 protein, were selected for further analysis of
DAX-1 transcriptional regulation. The changes in gene expression were reflected in
the amount of protein produced based on DAX-1 level changes, as seen in Figure 313. BAX saw an increase when DAX-1 was present and a decrease when DAX-1
expression was reduced, while BCL-XL saw a decrease with DAX-1 introduction and
increase with DAX-1 knock-down.
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Table 3-9. Comparison of candidate genes in MCF10A and MCF7 cells. Relative
increase in expression is indicated by an up arrow (), a decrease is indicated by a
down arrow (), and degree of significance is noted in parentheses. Significance is
either noted with a number of asterisks or labeled (n.s.) for not significant. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents
samples that were p<0.005, and a triple asterisk (***) represents samples that were
p<0.001. Not all treated samples were tested for each candidate genes.
MCF10A
MCF7
Type
Gene
(siDAX-1)
(pcDNA-DAX-1)

Anti-apoptotic

BCL-L2

 (*)

 (n.s.)

BCL-XL

 (**)

 (***)

BCL2-A1

 (***)

TNFα

 (*)

TRAF1

 (**)

BCL-L10

 (***)

TRADD

 (*)

 (**)

BAX

 (*)

 (**)

BAD

 (**)

 (n.s.)

BCL-XS

 (***)

 (**)

BCL-L1

 (***)

 (n.s.)

TRAF3

 (***)

 (n.s.)

 (***)

Pro-apoptotic

TNFR1

 (*)
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Figure 3-13. Western blot of candidate DAX-1 targets BCL-XL and BAX. BCL-XL,
the anti-apoptotic isoform of BCL-2, saw a decrease of protein expression with the
introduction of DAX-1, and an increase with the knock-down of DAX-1 expression.
BAX, a pro-apoptotic protein in the BCL-2 family, was observed to have an increase
in expression with the introduction of DAX-1, and a decrease in expression with the
knock-down of DAX-1 expression. GAPDH was used as a control.
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ChIP analysis of BCL-2 and BAX promoter regions
The promoter regions of BCL-2 and BAX were broken up into five regions,
with each region having a length of about 200-300 base pairs (Figure 3-7). Among
the regions tested, the presence of DAX-1 was detected in region 4 for BCL-2, that
corresponds to a section that spans a range of 442 to 225 base pairs upstream of the
BCL-2 transcription start site. This is shown in both a detectable band in agarose gel
electrophoresis of PCR samples using primers for region 4 (Figure 3-14A) and a
significant qPCR value when compared to both negative and positive controls
(Figure 3-14B). Results from region 3 were used in comparison as a section with no
detectable DAX-1 binding. Additionally, ERα is known to bind to the BCL2 promoter
based on a response to estradiol [60], and was similarly detected with significant
qPCR values.
DAX-1 was also detected in Region 2 of the BAX promoter region (results not
shown), which corresponds to a distance of 761 to 484 base pairs upstream of the
transcription start site.
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A.

B.

Figure 3-14. Chromatin immunoprecipitation (ChIP) experiments targeting
DAX-1 binding to the BCL-2 promoter. A. Agarose gel electrophoresis of PCR
products using primers targeting region 4 of the BCL-2 promoter and B. qPCR
results comparing the transcript amounts from ChIP experiments using IgG (as a
negative control), Histone H3 (as a positive control), DAX-1, and ERα antibodies. A
single asterisk (*) represents samples that were p<0.05, a double asterisk (**)
represents samples that were p<0.005, and a triple asterisk (***) represents
samples that were p<0.001. Error bars on qPCR results represent standard
deviation of the mean.
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Discussion
After verifying the success of DAX-1 expression modification in Chapter 2,
the influence of DAX-1 on apoptosis was tested through cell flow cytometry of cells
stained with Annexin V and PI (Figure 3-8). The increase in the number of apoptotic
cells in the entire population was comparable to a known apoptotic inducer BADGE,
confirming the association of DAX-1 with programmed cell death overall. There was
no additive effect of the combination of DAX-1 knock-in with BADGE treatment. The
treatment with both DAX-1 and BADGE appears to affect the same pathway, rather
than through different and alternate pathways. The BADGE reagent affects
apoptosis through TNFα very far upstream, therefore the DAX-1 target(s) would
likely lie downstream of the affected members of the pathway.
The MCF7 and MCF10A cells, treated as described in Chapter 2, served as the
opposing DAX-1 expression models. Genes that clearly showed mirrored expression
changes with the opposing models would be selected for further analysis, as these
changes strongly suggest a direct interaction as caused by varied DAX-1 expression,
rather than by the changes in the balance of apoptotic pathways. Among the
analyzed candidate genes, three showed significant mirrored changes: the large
BCL-2 isoform BCL-XL (Figure 3-9B and Figure 3-11A), TRADD (Figure 3-9G and
Figure 3-11D), and BAX (Figure 3-10A and Figure 3-12A). TRADD was ruled out for
further analysis because some of its regulation occurs post-transcriptionally, like by
gonadotropin-regulated testicular helicase (GRTH) interacting with TRADD mRNA
[61]. Meanwhile, research into BCL-2 and its family members has focused to a large
degree on transcriptional regulation due to key recognition elements [62], with
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some more recent research into post-transcriptional regulation [63]. For these
reasons, BCL-2 (interchangeably referred to as BCL-XL because of the large, antiapoptotic isoform) and BAX were selected for further analysis. The changes in gene
expression were reflected in the changes of the protein level (Figure 3-13). This not
only confirms that DAX-1 affects the protein level at the gene level, but also
reaffirms the idea that with DAX-1 apoptosis is promoted, while removing DAX-1
shifts away from an apoptotic profile.
The ChIP assays showed the presence of DAX-1 far upstream from the BAX
gene transcription start site, and relatively closer to the BCL-2 transcription start
site (Figure 3-14A). DAX-1 is unable to bind to the promoter directly on its own,
therefore it is likely DAX-1 binds to another transcription factor already occupying
the promoter, much like a “piggyback” fashion. Available ChIP assays also showed
that ERα is detected in the same region on the BCL-2 promoter, and this was
confirmed with our own experiments (Figure 3-14B). Given the strong relation of
DAX-1 and ER in breast cancer [64], the suggestion of an interaction between these
two proteins is highly likely. This can be further confirmed if DAX-1 would have less
of an effect on apoptosis in an ER negative breast cancer line. Additionally, this
means of interacting with apoptosis through ER interaction may also be reflected in
other key biological processes important to cancer cells. These results reveal a
fraction of an answer to the overall question of DAX-1’s positive contributions to
breast cancer, but strongly suggest that DAX-1 regulates the expression BCL-2 with
a transcription factor partner that, in turn, affects the apoptotic aspect of cell
survival.
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Chapter 4
Dax-1 Knock-down Effects on Pluripotent Gene Network in Mouse Embryonic
Stem Cells
Introduction
Stem cells are characterized by two defining properties: self-renewal and
pluripotency [65]. Self-renewal is the continued replication of a cell lineage,
allowing for preservation of population of cells, while pluripotency is the capacity of
a cell to differentiate into a variety of cell types, more notably into all three germ
layers: the ectoderm, mesoderm, or endoderm [66]. There are distinct pluripotent
stem cell types, distinguished by when the cells are harvested from an embryo. As
illustrated in figure 4-1, embryonic stem cells (ESCs) are harvested from the inner
cell mass (ICM) of a blastocyst after embryo day 5, while the outer cells can be
cultured into trophoblast stem cell (TSC) lines. As the blastocyst matures and the
ICM begins to divide into distinct layers by the fifth and sixth embryonic day,
embryonal carcinoma cells (ECCs) can be harvested from the embryo [67].
Embryonic stem cells are the most commonly used cells in mouse and human
stem cell research. In vitro culturing of mouse ESC was successfully developed to
maintain pluripotency of cells in tissue culture with the presence of leukemia
induction factor (LIF) [68]. The embryonic stem cells typically require the presence
of feeder cells that served as the source of LIF, but continued harvesting of mouse
ESC has allowed for specific lines that can be maintained without feeder cells [69],
which are adherent growth-arrested cells that are incapacitated and have the sole
purpose of releasing key nutrients required for the maintenance of the stem cell
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state [70]. These cell lines can be implanted in a developing embryo and still
differentiate into all three types of germ cells, allowing for genetic modification of
entire organisms.
Established ES cell lines are maintained by complex protein networks [71,
72], with distinct key transcription factors such as Oct3/4 [73], Sox2 [74], and
Nanog [75] that strongly drive the maintenance of pluripotency, and additional
factors such as Stat3 [76] and c-Myc [77] that contribute to self-renewal. These
connections were made through various knock-down studies, both of individual and
a combination of candidate factors [78, 79]. Through these studies, no one single
gene was the sole factor for maintaining the pluripotent state. Likewise, since the
maintenance of a pluripotent state has a number of factors centered in the complex
interactions, it was found that reversing differentiated adult mouse fibroblasts
needed a combination of some of these key factors (OCT3/4, Sox2, c-Myc, and Klf4)
to return stem cell-like state [80]. Untangling the network of transcription factors
that keeps pluripotency in check therefore opens up a range of therapeutic
possibilities in the medical world.
When Dax-1 was knocked down in mouse stem cells, it was found that the
loss of Dax-1 alone was not sufficient to change the phenotype of the population of
cells, just like the other key factors. However, there were interactions with many key
pluripotency genes that brought Dax-1 into the spotlight as an important
contributor to the pluripotent state [81].
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Figure 4-1. Stem cell origins in the mammalian embryo. Pre-ICM (inner cell
mass cells) transition to ICM cells during blastulation at embryonic day 3-4. After
this occurrence, ES cells can be harvested from the organism and established in
vitro.
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Target Genes
Research carried out previously in the Tzagarakis-Foster lab identified a
number of notable genes that Dax-1 appears to interact with, based on changes in
gene expression between wild-type mESCs and Dax-1 knocked-down mESCs [82].
Candidate genes were selected based on observations of a significant fold change in
expression through tests in a pluripotency PCR array. The known roles and
contributions to overall cell activity of a subset of the selected genes are elaborated,
and give hints to the mechanisms by which Dax-1 is contributing to pluripotency, as
shown in Table 4-1. Furthermore, additional genes of interest were added to the
pool of genes examined based on known interactions with Dax-1 in contexts outside
of stem cells.
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Table 4-1. Dax-1 candidate target genes in mESC and their role in mediating
pluripotency and differentiation.
Target Gene
Description
Nanog
Pou5f1;
OCT3/4
GATA6
SOX2
SOX9
SOX17
T
Lefty2

AMH

Key player in maintenance of pluripotency and self-renewal
[83]
Key player in maintenance of pluripotency and self-renewal
[73, 84]
Drives differentiation and organogenesis [85]
Known to interact with Oct3/4; together with SOX3, encodes the
protein SOXB1. Key play Key player in maintenance of pluripotency
and self-renewal [86]
Known to interact with DAX1 in male sexual development through
the expression of SRY from the Y chromosome [87]
Drives differentiation and cell fate determination [86]
Brachyury is part of the family of T-box transcription factors;
contributes to the formation and organization of the mesoderm
layer during embryogenesis; also refered to as T-Brachyury [88]
Part of the TGFbeta family, which as a whole is involved in cell
growth, cell differentiation, apoptosis, homeostasis; required for the
left-right asymmetry determination of organogenesis [89]
Anti-Mullerian hormone, also known as MIS (Mullerian inhibiting
substance), is part of the TGFbeta family as well. It is known
primarily for its role in male sexual development through inhibition
of Mullerian ducts, allowing for proper development of Wolffian
ducts. [90]
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Materials and Methods
RNA and cDNA extraction
mESC were treated using siRNA and CRISPR experiments as described in
Chapter 2. The mRNA of these cells were extracted and isolated as described
in Chapter 3.

Target Genes
Based on the information produced by previous studies [82] and additional
genes of interest, the following table lists the forward and reverse primers
used for the isolation of gene fragments and measurement of overall gene
expression by quantitative PCR.

94

Table 4-2. Pluripotency candidate gene primers.
Gene

FWD

REV

Source

Dax-1

TCCTGTACCGCAG
CTATGTG
ACAGCCGCATCTT
CTTGTGCA
CCATCACCATCTT
CCAGGAGCG
TTCTTGCTTACAA
GGGTCTGC
ATGCTGTCCGGCC
TGCCCTA
CTGCGCTTCAAGG
AGCTAAC
CTCCCGAGGAGTC
CCAGGACAT
ACAAGAGAATTGG
GAGGGGT
AGGAAGCTGGCAG
ACCAGTA
TGGAACCTCCAGT
AAGCCAG
GGGAGACTGGAGA
ACAGCAG
CATGAAGTCCCTG
TGGCTTT

TGCAAGTGCAGGTGA
TCTTG
GGCCTTGACTGTGCCG
TTGAA
AGAGATGATGACCCT
TTTGGC
AGAGGAAGGGCGAGG
AGA
GTTCACGCACTCGCGG
CTCT
CCAGGCCTGACACATT
TACC
GATGGTGGTCTGGCTG
AACACCT
AAAGCGTTAATTTGG
ATGGG
TCCACGAAGGGTCTCT
TCTC
TCAGATGTCTGGAGG
TGCTG
GGTGGAGGCTCTTGG
AACTT
TGCAGTAGACTGCTCA
GGACC

[82, 91]

GAPDH (1)
GAPDH (2)
Nanog
GATA6
T-Brachyury
Oct3/4
SOX2
SOX9
SOX17
AMH
Lefty2

[82]
Construct
[91]
[82]
[81]
[81]
mouseprimerdepot
mouseprimerdepot
mouseprimerdepot
mouseprimerdepot
mouseprimerdepot
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Polymerase Chain Reaction (PCR)
Annealing temperatures were optimized using GoTaq Green Master Mix
(Promega), Taq 2X Master Mix (New England Biolabs), and FailSafe PCR
System (Epicentre) kits. Reactions were run with the same protocol listed in
Table 3-3.

Real-Time PCR (qPCR) and Statistical Analysis
Reagents and equipment used for RT-PCR experiments and statistical
analyses were carried out as described in Chapter 2.

96

Results
Gene expression changes with siRNA Dax-1 knock-down
After treating the mouse embryonic stem cells with siRNA transcripts in
order to modify high Dax-1 expression, as described in Chapter 2, collected cDNA
was used for qPCR analysis of candidate target pluripotency genes (Figure 4-2).
Among the genes tested, Nanog and lefty2 saw a significant increase in relative
expression after siDax-1 treatment. Expression of the genes SOX2, SOX17, GATA6,
and T-Brachyury saw a significant decrease (Figure 4-2 B, C, F, and G), while OCT3/4
and SOX9 (Figure 4-2 H and I) saw a non-significant decrease in expression. The
expression of AMH (Figure 4-2D) did not change. These changes are also
summarized in part of Table 4-4.
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A.

B.

C.

D.
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F.

G.

H.
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Figure 4-2. qPCR results of siRNA Dax-1 knock-down mESC. Graphs correspond
to the candidate genes: A. Nanog, B. SOX2, C. SOX17, D. AMH, E. Lefty2, F. GATA6, G.
T-Brachyury, H. OCT3/4, and I. SOX9. A single asterisk (*) represents samples that
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR
results represent standard deviation of the mean.
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Gene expression changes with CRISPR-Cas9 treatment
Following the CRISPR-Cas9 treatment described in Chapter 2, stable cells
that were treated with CRISPR guide 3 that targeted an early section of exon 1 and
showed Dax-1 knockout were harvested and used for analysis of the candidate
genes (Figure 4-3). Nanog (A), Lefty2 (E), and T-Brachyury (G) saw a significant
increase in expression with the disruption of Dax-1 expression. SOX2 (B), SOX17 (C),
GATA6 (F), OCT3/4 (H), and SOX9 (I) saw significant decreases in expression.
Lastly, AMH (D) showed no change in expression when comparing untreated to
treated samples. These results are also summarized in Table 4-3.
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Figure 4-3. qPCR results of CRISPR Dax-1 knock-down mESC. The cells used
were treated with guide 3, targeting exon 1 of Nr0b1. Graphs correspond to the
candidate genes: A. Nanog, B. SOX2, C. SOX17, D. AMH, E. Lefty2, F. GATA6, G. TBrachyury, H. OCT3/4, and I. SOX9. A single asterisk (*) represents samples that
were p<0.05, a double asterisk (**) represents samples that were p<0.005, and a
triple asterisk (***) represents samples that were p<0.001. Error bars on qPCR
results represent standard deviation of the mean.
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Table 4-3. Comparison of siRNA and CRISPR Dax-1 candidate gene results.
Relative increase in expression is indicated by an up arrow (), a decrease is
indicated by a down arrow (), no change indicated by an x-symbol (), and degree
of significance is noted in parentheses. Significance is either noted with a number of
asterisks or labeled (n.s.) for not significant. A single asterisk (*) represents samples
that were p<0.05, a double asterisk (**) represents samples that were p<0.005, and
a triple asterisk (***) represents samples that were p<0.001.
Gene
siRNA
CRISPR-Cas9
Nanog

 (**)

 (***)

SOX2

 (***)

 (***)

SOX17

 (***)

 (***)

AMH

 (n.s.)

 (n.s.)

Lefty2

 (***)

 (***)

GATA6

 (***)

 (***)

T-Brachyury

 (***)

 (***)

OCT3/4

 (n.s.)

 (*)

SOX9

 (n.s.)

 (*)
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Discussion
Using the mESC samples that were treated as outlined in Chapter 2, selected
candidate genes were examined for changes in gene expression. In order to further
validate the expression changes, two different methods were used to knock-down
Dax-1 expression. The comparison using the cDNA of both methods to observed
gene expression changes are shown in Table 4-3.
Overall, both methods were successfully able to knock-down Dax-1
expression, both transiently through siRNA and permanently through CRISPR-Cas9.
It is very clear that Dax-1 is not a master regulator, since expression of key markers
such as Nanog surprisingly increased, while others such as OCT3/4 experienced
only a slight decrease in expression. However, changes in particular genes involved
with specific cell fates suggest that Dax-1 is not a key regulator because it appears to
only be involved with certain pathways towards differentiation. For example, the
knockdown of Dax-1 appears to have strong effect on the expression of Lefty2, a
gene involved in proper asymmetric development of cells that differentiate to be
part of the mesoderm [89]. Another gene that was especially affected with the longterm removal of Dax-1 was T-Brachyury, which is required for mesoderm formation
[92].
The increase in expression in these genes involved with mesoderm
formation, despite the maintenance of key genes, may be enough to tip the scales
towards differentiation within a population of cells. To confirm if Dax-1 has the
strongest interaction with mesoderm genes, the candidate list can be expanded to
include genes involved with this specific fate should be investigated in the future.
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To further confirm if the interactions with genes of interest are direct or not,
additional ChIP experiments can be carried out as described in Chapter 3. However,
it should be noted that there are research groups who have already carried out
large-scale ChIP assays with publically accessible results. This allows for a
computer-based approach to sorting through data to confirm Dax-1 interactions
based on detection in regulatory regions of genes.
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Chapter 5
Functional enrichment analysis of Dax-1 ChIP-seq high-throughput data
Introduction
As described in Chapter 3, chromatin immunoprecipitation assays are often
employed to investigate whether a protein of interest is present in complex to
specific promoter regions of select target genes. The samples resulting from X-ChIP
are typically used for analysis of a small number of regulatory regions, often with
primers flanking a region designated by the user. On a slightly larger scale, ChIPchip allows one to analyze the resulting DNA fragments on a chip array with a preselected set of primers for known regulatory regions. When scaled up even more
and paired with massive parallel sequencing, conventional ChIP becomes ChIP-seq,
and allows for genome wide functional analysis. Using this final method, binding
sites of the protein of interest are sequenced and are associated with genes from
numerous gene ontology databases using computer annotation tools. The wealth of
these data is greatly untapped, and to repeat experiments when there is information
available would prove to be wasteful and costly.
A well-known repository for data sets from published papers is the National
Center for Biotechnology Information’s Gene Expression Omnibus (GEO), online at
http://www.ncbi.nlm.nih.gov/geo/, where array and sequenced based data are
collected and can be searched for with keywords or an assigned accession number.
New resources such as NURSA (Nuclear Receptor Signaling Atlas), online at
http://www.nursa.org/, provide a way for researchers to seek specifically for
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information pertaining to specific nuclear hormone receptors, with raw information
organized by target rather than a massive repository to comb through.
In relation to Dax-1, a search through GEO yielded both ChIP-chip and ChIPseq experiment results in mESC, the latter of which was obtained for further
analysis [93]. The outcome of this analysis can be used not just to validate earlier
studies in pluripotency, which were limited to a small set of genes in a PCR array,
but also allows for new characterization of Dax-1 in mouse embryonic stem cells.
The raw ChIP-seq data and other types of sequence data can be mapped onto the
mouse genome through the use of computer annotation tools. These tools associate
given sequences (also referred henceforth as peaks) where the protein of interest
was bound to the regulatory regions of genes and calculate how accurate the
enrichment of a set of genomic regions is. There are numerous gene annotation
tools that use different types of statistical methods, genome databases, and gene
ontology databases to map provided sequence data.
Like humans, the mouse genome is comprised of only ~5% protein-coding
regions, with the remainder “non-coding” DNA consisting of untranslated regions
with unknown purpose, non-protein-coding genes, chromosomal structural
elements, and regulatory sections [94]. Depending on the means of statistical
analysis, there is a possibility for a false association when a test allows for an
extensive regulatory region to be associated with a gene. These regions are also
known as “gene deserts”, and depending on the database, can be as large as a million
base pairs away from a gene.
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Statistical Analysis
The hypergeometric method is a standard gene enrichment test used by
annotation tools such as DAVID and GO Term Finder. The formula, as shown in
Figure 5-1A, tests if a gene with a number of peaks in an associated region is
enriched with annotations out of a full set of genes in a genome. The values from the
formula are as follows: N for the number of genes in the genome, n for the number
of genes in a test gene set, Kπ for the number of genes in the genome with the
annotation π, and kπ for the number of genes in a test gene set with annotation π.
The p-value calculated by this method, using the formula in Figure 5-1A, is the
probability of choosing kπ or more genes with annotation π when n genes are
randomly selected from the genome. There is a heavy bias in this method to only
associate peaks with genes if it falls in a proximal region, so many distal association
are missed.
The binomial method is another means of statistical analysis. Genes are
assigned various regulatory region size, and the p value calculated in the formula in
Figure 5-1B accounts for the probability of given peaks to fall within the range of
numerous regulatory regions. This can provide novel gene associations, but this bias
towards distal binding peaks can lead to false links.
GREAT, which stands for genomic regions enrichment of annotations tool, is
an annotation tool available online at (http://bejerano.stanford.edu/great/public2.0.2/html/) [95]. Running initial data through GREAT analysis provides the user
with various calculated values from each statistical method. Among these values,
there is a false discovery rate (FDR) q-value, which is obtained by selecting for an

110

ideal p-value among results. These corrected values account for false reads from a
single method and give a more accurate ranking of the strength of gene association.
In order to overcome the errors that come from each individual test even
after correcting for possible false reads, provided data from GREAT are further
processed to find ontology terms that are significant by both tests (B ∩ H). The
extracted information is processed through R, a computer language and software
environment useful for overall data analysis and graphics [96]. Users can process
information through their own programming, or using available packages to
implement statistical techniques.
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A.

B.

C.

Figure 5-1. Statistical analysis of ChIP-seq data using the GREAT online
annotation software. This software utilizes the formula of two tests, A.
hypergeometric and B. binomial. C. GREAT carries out each method separately in
order to associate a genomic peak or number of peaks with a single gene, obtained
from an ontology annotation [97].
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Materials and Methods
In collaboration with Vaishali Chaudhuri, a student enrolled in HS617
(Projects in Statistical Computer for Biomedical Data Analytics) at the University of
San Francisco, publically available data of Dax-1 ChIP-seq data on NCBI’s Gene
Expression Omnibus (GEO) database were analyzed. Data sets associated ascension
numbers GSM1183116 and GSM1183117 pertaining to Dax-1 binding events in J1
mouse embryonic stem cells were used [93]. The available data online are in .wig
format, which is an older format containing data such as GC percent, probability
scores, and transcriptome data. BED files of the replicate experiments carried out
encoding detected Dax-1 peaks for the entire mouse genome was provided by the
Kim lab at UT Austin.
Analysis was carried out using the GREAT annotation tool, available online at
(http://bejerano.stanford.edu/great/public-2.0.2/html/), where the data are
provided as a BED file for input. The program associates the provided sequences
with regulatory regions of genes, both proximal and distal, using numerous gene
ontology databases and the two distinct statistical methods described in the
background section. GREAT version 3.0.0 was used to analyze the Dax-1 ChIP-seq
data from both BED files with parameters listed in Table 5-1, in order to find the
association of provided peaks with gene ontologies.
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Table 5-1. Parameters for GREAT version 3.0.0 online analysis.
Species Assembly

Mouse: NCBI build 38 (UCSC mm10, Dec/2011)

Test regions

DAX_BED1, DAX_BED2 [93]

Background Regions

Whole Genome

Association rule settings

Basal plus extension
Proximal: 5.0 kb upsteam, 1.0 kb downstream
Distal: 1000.0 kb

The GREAT website then gives an output of associated genes grouped by the
different gene ontologies, ranked by the calculated enrichment through both the
binomial test and hypergeometric test. The results from the selected ontologies, as
shown in Figure 5-2 were compiled from individual .tsv files into a single .csv file.
This output was then run through three distinct packages in the R-language
program: hierarchial cluster analysis [98], K means cluster analysis through ggplot
[99], and principal component analysis [100].
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Figure 5-2. Selected Ontology results from processing DAX1_BED1 file through
the online GREAT program.
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Results
Following processing through the R programming language, the top five
ontologies were selected for further analysis (Figure 5-3). These ontologies had high
p-values in both statistical methods, and therefore show the greatest confidence of
Dax-1 influence within the category. The overall descriptions of associated
ontologies are described in Table 5-2. The highest ranking ontology encompasses
genes that are expressed in differentiated cells that are part of the trophectoderm,
followed by genes that lose their expression before birth or at birth, once the
embryo no longer needs to develop. The next three categories are more broad, with
two (Gen_V6.5 and Gen J1) containing genes that were down-regulated in late stages
of differentiation in two distinct mouse embryonic stem cell lines, and one involving
genes that participate in the platelet-derived growth factor receptor signaling
pathway.
The genes within the selected ontologies were further narrowed down in
Table 5-3 based on the distance of Dax-1 binding from the transcription start site
(TSS). Genes were arbitrarily selected if the binding occurred within 6,000 base
pairs before the start sites, and up to 2,000 base pairs after the start site. Genes that
were previously studied in Chapter 4 and that appeared within the top ontologies,
namely Nanog, Pou5f1, SOX2, and T, were also selected in Table 5-4.
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Figure 5-3. Top five interactions in Dax-1 ChIP-seq interactions obtained
through analysis of ontology data from GREAT by Dynamic Tree Cut, ggplot2,
and PCA packages in R language. Image generated by V. Chaudhuri.
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Table 5-2. Top five Interactions in Dax-1 ChIP-seq interactions.
Rank

2

Biological Description
Process
TS5_Troph These genes are
ectoderm
expressed and play a role
in differentiated cells that
are part of the
trophectoderm.
TS5_EEC
Extraembryonic
components consist of
genes that may be lost
before birth or will be
discarded at birth, or
when the embryo
becomes an independent
organism.

3

Gen_V6.5

4

PDGFR

5

Gen_J1

1

Regions
205

Genes Ontology
Source
63
MGI Expression:
Detected

214

67

MGI Expression:
Detected

Genes down-regulated
203
during late stages of
differentiation of
embryoid bodies from
V6.5 embryonic stem
cells.
Platelet-derived growth
73
factor receptor signaling
pathway; The series of
molecular signals
generated as a
consequence of a plateletderived growth factor
receptor binding to one
of its physiological
ligands.
Genes down-regulated
196
during late stages of
differentiation of
embryoid bodies from J1
embryonic stem cells.

83

MSigDB
Oncogenic
Signatures

16

GO Biological
Process

82

MSigDB
Oncogenic
Signatures
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Table 5-3. Selected genes from the top five ontologies. Regions with negative
values are peaks before the gene transcription start site (TSS), and positive base
pair values are distances after the gene TSS. Genes that showed Dax-1 peaks within
6,000 base pairs before TSS and 2,000 base pairs after TSS are shown.
Gene
Region (bp)
Ontology
Acacb
+1,355, +5,318
(5) Gen_J1
Ankrd10 -5,182
(5) Gen_J1
Atp1b1
-94,421, -92,777, -64,303, -60,187, -45,391, (2) EEC
36,143, -25,414, -2,739, +12,409, +79,738,
+81,235
Avpi1
-7,164
(3) Gen_V6.5
Bcl3
-798, +7,504
(3) Gen_V6.5
Cbx7
-1,159, +27,487, +30,030
(3) Gen_V6.5
Cdh1
-3,617, +3,593, +11,996
(2) EEC
Csrnp1
-276, +25,671
(3) Gen_V6.5
Dppa2
-1,381
(3) Gen_V6.5
Dppa5a -6,686, -3,389, -1,095, +3,296, +7,485, +8,252
(2) EEC
Dpys
+893, +76,433
(5) Gen_J1
Eras
+1,451
(5) Gen_J1
Etv4
-557, +7,171, +8,185, +12,655
(3) Gen_V6.5
Fbxo15
-851
(3) Gen_V6.5
Fgfr2
+1,368. +12,718, +14,001
(2) EEC
Frs2
-3,980
(1) Trophectorderm,
(2) EEC
Gbx2
-2,861
(3) Gen_V6.5, (5)
Gen_J1
Gli2
-353,788, 351,438, -345,108, -294,626, -251,793, - (3) Gen_V6.5, (5)
248,600, -112,886, -98,929, -94,242, -28,753, Gen_J1
22,877, -1,856, +4,415, +69,593, +405,274,
+410,581
Gpa33
-4,837, +5,088, +12,317
(3) Gen_V6.5
Gtf2ird1 -71,300, +55, +11,081, +17,489, +116,355,
(2) EEC
+119,412, +123,640, +127,110
Hspg2
-6,950, +1,653, +11,424, +20,048, +28,713
(2) EEC
Icam1
-1,113
(3) Gen_V6.5, (5)
Gen_J1
Iqgap1
-40,825, -19,882, +163, +19,419, +56,666
(2) EEC
Jam2
-4,230, +5,299
(3) Gen_V6.5, (5)
Gen_J1
Kank2
-409, +30,112
(2) EEC
Kat2b
-5,197
(3) Gen_V6.5
Kat7
-2,063
(2) EEC
Kdm5b
-4,567, +3,786, +10,410
(2) EEC
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Mras
Msrb2
Mybl2
Myc
Nanog

+1,698, +12,426, +16,551, +19,849, +45,946
-70,042, +118, +9,270
-22,846, -2,379, +12,610, +20,795
-6,505, +24,556, +25,544, +107,426, +176,743,
+973,579
-44,193, -17,124, -4,791, +34

Notum

-2,804

Nr0b1

-4,311, +1,854

Ntn1
Pcolce

-355, +6,644, +52,524
-2,199, +555

Pdgfc
Pdgfrb
Pou5f1

-13,859, -3,326
-2,085
-20,232, -15,487, -3,252, -1,985, -994, -100

Ppcs
Prmt6
Rif1

-295
-495
-733

Sall4
Sema4b
Slc39a4

-86,804, -84,580, -74,561, -24,142, -19,141, 12,691, -2,340, +2,037
-56,334, -611, +34,730
-798

Slc4a3
Socs3

+129, +55,687, +258,304, +390,568, +482,891
-6,503, -3,615, +6,947, +36,854, +80,486

Sox13

-134,922, -99,881, -4,606, -3,529, +25,571

Sox2
Spry4
Syncrip
T

-3,574, +18,648, +85,086, +106,847, +108,032,
+110,438, +111,406, +787,897
-1,087, +25,127, +27,298, +79,109
-2,124
-19,833, -4,154

Tcea3

-1,457

Tcf15

-1,242, +34,026, +35,029, +35,952, +36,925,
+46,163

(3) Gen_V6.5
(3) Gen_V6.5
(2) EEC
(3) Gen_V6.5
(1) Trophectoderm,
(2) EEC
(3) Gen_V6.5, (5)
Gen_J1
(3) Gen_V6.5, (5)
Gen_J1
(5) Gen_J1
(3) Gen_V6.5, (5)
Gen_J1
(4) PDGFR
(4) PDGFR
(1) Trophectorderm,
(2) EEC
(5) Gen_J1
(5) Gen_J1
(1) Trophectorderm,
(2) EEC
(2) EEC
(3) Gen_V6.5
(1) Trophectorderm,
(2) EEC
(5) Gen_J1
(3) Gen_V6.5, (5)
Gen_J1
(1) Trophectorderm,
(2) EEC
(1) Trophectorderm,
(2) EEC
(3) Gen_V6.5
(5) Gen_J1
(1) Trophectorderm,
(2) EEC
(1) Trophectorderm,
(2) EEC, (3)
Gen_V6.5, (5) Gen_J1
(3) Gen_V6.5, (5)
Gen_J1
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Tdgf1
Tet1
Tfap2c

-1,994
-1,158, +681, +1,996, +3,457 +6,027
-53,052, -32,751, -28,800, -4,830, +27,812,
+44,801, +64,252, +278,876, +322,038
Tmem79 -2,377
Trh
-2,924, -1,883
Ttc39b
-5,907, -4,517, +7,385
Tubb2b -1,447, +20,578
Tubb3
+923
Vegfc
Zbtb45
Zfp219

-976
-4,675
-1,921

Zfp296

-1,463

Zfp42
Zfp57

-26,631, -13,963, -140
-6,871, +27

(5) Gen_J1
(5) Gen_J1
(1) Trophectorderm,
(2) EEC
(3) Gen_V6.5
(5) Gen_J1
(3) Gen_V6.5
(5) Gen_J1
(3) Gen_V6.5, (5)
Gen_J1
(5) Gen_J1
(3) Gen_V6.5
(1) Trophectorderm,
(2) EEC
(1) Trophectorderm,
(2) EEC
(3) Gen_V6.5
(3) Gen_V6.5
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Table 5-4. Genes from the top five ontologies that overlap with mESC
pluripotency project. Regions with negative values are peaks before the gene
transcription start site (TSS), and positive base pair values are distances after the
gene TSS. Possible significant sites that are within a reasonable distance from the
TSS are underlined.
Gene

Region (bp)

Nanog

-44,193, -17,124, -4,791, +34

Pou5f1

-20,232, -15,487, -3,252, -1,985, -994, -100
-3,574, +18,648, +85,086, +106,847, +108,032, +110,438, +111,406,

SOX2

T

+787,897
-19,833, -4,154
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Discussion
Analyzing the results of ChIP-seq allowed for a greater understanding of the
broad influence Dax-1 has within the mouse embryonic stem cell model. The
presence of the Dax-1 protein in a regulatory region of a target gene reveals possible
direct interactions and influence on transcription. The resulting gene list (Table 5-3)
does not encompass all of the genes associated with Dax-1 binding within the
selected ontologies, because the GREAT program allows for extremely distal
binding. While distal binding accounts for more complex interactions, more
proximal sites are ultimately easier to investigate and confidently draw any
conclusions from.
Overall, the results shed some light on why Dax-1 appears to have a strong
but not absolute influence on pluripotency. While it has some interactions with
master regulators, it also appears to affect a subset of genes involved in a specific
differentiation route towards maturation into the trophectoderm. Genes involved
with development of the trophectoderm are among the first to be activated, since
these cells are required for implantation of the embryo and eventually give rise to
some of the placenta [101]. Therefore, modification of Dax-1 seems to heavily
influence only one route, and other cells with transcription factors favoring any
other route of differentiation may be less influenced by the Dax-1 absence.
While the genes investigated in Chapter 4 were selected from previous
research, they were but a small number out of the total number of identified
interactions. Cross-referencing of candidate genes with the targets found through
ChIP-seq analysis made up for the lack of labor-intensive ChIP experiments for each
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individual gene. Among the candidates from Chapter 4, Dax-1 was found to be
present within the regulatory regions of Nanog, Pou5f1 (aka OCT3/4), Sox2, and T
(Table 5-4).
Lastly, there are genes that were not previously identified as candidate
targets through any previous array or project. There are those that fall within the
realm of pluripotency and expand on the interactions within that phenomenon in
stem cells, but additional ontologies available through the GREAT program revealed
Dax-1 interactions with genes involved in a range of diseases. Manipulation of the
statistical analyses can account for similar ontologies with great overlap of genes,
and allow for different ontologies to gain a higher relative rank. Given that the
mouse model is often used to further understand human models, interactions with
possible novel genes can answer a myriad of questions.
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End Summary
DAX-1 serves as a great protein of interest, with unique properties as an
orphan nuclear hormone receptor. Its specific expression in cell types, especially
stem cells and certain cancer cells, gives rise to questions about what molecular
pathways in which it could possibly be involved.
These interactions were investigated in a human model with two types of
breast cells by changing the endogenous expression of DAX-1, based on studies that
revealed DAX-1 involvement in cell survival pathways. Apoptosis appeared to be the
process of interest, due to changes in key genes and a similar result to that of a
known small molecular inhibitor treatment. Following qPCR assays to observe
mirrored expression in cell culture models that were treated to have opposing
expression of DAX-1, candidate genes were selected for further analysis. BCL-2, an
anti-apoptotic member of the BCL-2 protein family, was found to have DAX-1
present along its promoter, and it is likely that this regulation is through interaction
with ERα. Therefore, one way that DAX-1 influences apoptosis is through BCL-2
transcriptional regulation.
In mouse embryonic stem cells, Dax-1 had been found to play a role in
pluripotency. Using two different knock-down methods, siRNA and CRISPR-Cas9,
candidate genes selected from earlier studies within the Tzagarakis-Foster Lab were
tested for changes in gene expression. With the exception of the T gene, changes in
expression for both types of knock-down treatments were similar and strongly
suggested that Dax-1 interacts with subsets of genes involved in specific
differentiation pathways.
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And lastly, the scope of Dax-1 regulated genes was expanded through
statistical analysis of available Dax-1 ChIP-seq data, using the R-language and
various packages to manipulate data. After first being run through an online
program GREAT to find ontologies that are statistically significant through two
analysis methods, binomial and hypergeometric, the results from each method were
further processed to find overlapping results to confirm Dax-1 association. Resulting
genes reveal interactions with not only candidate genes from small scale
experiments, but also open up studies for uninvestigated and novel Dax-1
transcriptional interactions.
Based on these results, DAX-1 is not limited to involvement with a single
biological process, but is restricted enough to be a therapeutic target in an
individual cell type. Apoptotic observations in the human breast cells were not seen
in the mouse embryonic stem cells, and vice versa. The interactions within the
breast cancer cells, not only with ERα but other key steroid receptors such as AR
[102], strongly connect DAX-1 as a gene target within cancer. DAX-1 and other
orphan nuclear hormone receptors are increasingly becoming not just therapeutic
targets [103], but also markers of prognosis and how successful therapy is [104].
Hopefully, these findings add to the rich story that continues to develop in the DAX1 related research field.
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